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Abstract 
Antibiotic Resistance and Prescribing in Children 
Hospitalized with Community-Acquired Pneumonia 
Lilliam Vanessa Ambroggio 
 
 
 
 
 Pneumonia causes more deaths in children under 5 years old worldwide than 
malaria, AIDS and measles combined. Community-acquired pneumonia occurs annually 
in about 4 million children under 5 years old in the United States and is typically caused 
by Streptococcus pneumoniae. Substantial variability exists in the management of this 
disease. The variability in the management of pediatric pneumonia is due to all aspects of 
the disease, including but not limited to the numerous agents that cause the disease, the 
lack of a gold standard diagnostic test and the lack of national guidelines regarding 
treatment. This variability in treatment has resulted in the use of unnecessarily broad 
spectrum antibiotics leading to more resistant organisms becoming more prevalent in the 
community. The prevalence of penicillin resistance in S. pneumoniae has increased over 
the past decade, but penicillin is found to be still effective clinically in treating 
nonsusceptible pneumococci. Accredited hospitals in the U.S. document antibiotic 
susceptibility patterns of S. pneumoniae and it is unclear whether the hospital-reported 
susceptibility patterns influence the clinician’s prescribing patterns. It is also unknown if 
prescribing broader spectrum antibiotics to patients have similar outcomes to patients 
who are prescribed narrower spectrum antibiotics, for instance penicillin alone. This 
research examines the variability that exists in managing pediatric pneumonia by using 
x 
existing data from 20,000 patients collected from over 30 tertiary care children’s 
hospitals across the United States. 
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Chapter 1: Literature review of pediatric community acquired pneumonia 
 
 1.1 INTRODUCTION 
 Community-acquired pneumonia occurs annually in about 156 million children 
under 5 years old, worldwide. In the United States alone, approximately 4 million 
children are diagnosed with pneumonia resulting in greater than 150,000 hospitalizations 
each year in the United States, with approximately 60,000 attributable to Streptococcus 
pneumoniae 1-3. Empiric therapy is the most common way to treat pediatric pneumonia as 
the causative agent is usually unknown due to the difficulty of specimen collection. As a 
consequence, there is substantial variability in empiric therapy.  
 CAP is a highly treatable disease. Typically, treatment decisions are made based 
on clinical manifestations of the disease present in the patient and the known 
epidemiology of potential pathogens that exist in the community. Substantial variability 
exists in the management of pediatric CAP due to all aspects of the disease, such as the 
numerous agents that can cause CAP, the lack of a gold standard diagnostic test, and the 
lack of national guidelines for the management of childhood pneumonia. Tools such as 
hospital antibiograms were created to disseminate information on drug resistant 
pathogens, either bacterial or viral, that have been isolated in the hospital. This 
information can guide the physician with the decision of which treatment to administer. 
The actual influence of hospital antibiograms in guiding prescribing practices has not 
been well described or quantified in the literature.   
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 The aim of this review was to present the most recent epidemiology, etiology, and 
diagnostic findings for childhood pneumonia with a specific focus on antibiotic 
prescribing practices.  
1.2 EPIDEMIOLOGY 
  Community-acquired pneumonia (CAP) can be defined as “the presence of fever, 
acute respiratory symptoms, or both, plus evidence of parenchymal infiltrates [change in 
soft tissue in the lung] on chest radiography” due to microbial agents acquired outside of 
the hospital 4, 5. Pneumonia accounts for 20% of mortality in children worldwide 6. In 
developing countries the incidence of pneumonia is tenfold higher than in developed 
countries; 70% of these deaths occur in sub-Saharan Africa and South East Asia 7, 8. The 
annual incidence of pneumonia in children under 5 in the U.S. ranges from 20 to 55 cases 
per 1000 and 16 to 22 cases per 1000 for children 5 years or older 6.  
  In developed countries less than 1% of pediatric CAP cases are fatal, but 
morbidity associated with CAP can be quite substantial 9. CAP is estimated to account for 
3-18% of all pediatric admissions into hospitals in the developed world 10. Morbidity 
associated with CAP may be measured by “length of symptoms, time off school and, for 
those admitted to hospital, time in hospital, duration of oxygen requirement, numbers 
requiring intensive care and time to recovery as well as complications of the disease and 
of the treatment” 10. Certain risk factors, such as children who are predisposed to 
respiratory tract infections (children with asthma or cystic fibrosis), 
immunocompromised patients , sickle cell disease, malignancy, or who were born with 
congenital anomalies lead to a more complicated form of the disease 6.  
1.3 ETIOLOGY 
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 The etiology of CAP is difficult to obtain on an individual-level basis therefore 
physicians depend on etiological studies that have been stratified by the age of the child 
(TABLE 1).  The majority of CAP cases in newborns (birth to 20 days of age) are caused 
by group B streptococci, gram negative enteric bacteria, cytomegalovirus, Listeria 
monocytogenes, or herpes simplex virus acquired perinatally. In infants (21 days to 3 
months of age), CAP is typically caused by Chlamydia trachomatis, different respiratory 
viruses (e.g. respiratory syncytial virus, influenza A or B, parainfluenza viruses 1, 2, and 
3, and adenovirus), bordetella pertussis, or staphylococcus aureus. In young children (3 
months to 5 years) and school-aged children (5 to 15 years), the most typical bacterial 
cause of CAP is Streptococcus pneumoniae and, less commonly, respiratory viruses, 
Haemophilus influenzae, Mycoplasma pneumoniae and Chlamydophila pneumoniae 4, 6, 7. 
Tuberculosis, although a relatively uncommon cause in all age groups, is also considered 
a potential cause in endemic areas 11. The etiology of pneumonia is also highly influenced 
by seasonal patterns, with influenza being more common as a causative agent in winter 
months 9, 11. The leading bacterial cause of pneumonia in all age groups, with the 
exception of newborns, is Streptococcus pneumoniae 4, 9.  
 Of one hundred eighty-four immunocompetent children, ages 2 months to 17 
years (median: 33 months), who were admitted to Children’s Medical Center in Dallas, 
TX for CAP, 60% of these children were found to have typical respiratory bacteria as the 
causative agent; 73% of these bacterial cases were caused by Streptococcus pneumoniae. 
In addition 23% of the overall cases were found to be caused by mixed bacterial and viral 
infections 12. A similar study conducted in children hospitalized for pneumonia in 
Finland, found that 37% of the total cases (n=254) with ages ranging from 1 month to 
4 
children older than 5 years old were infected with S. pneumoniae and only 7% were 
infected  Mycoplasma pneumoniae 13.  
 Although there has been a 90% reduction in the incidence of invasive pediatric 
pneumonia and a 23% reduction of non-invasive pediatric pneumonia due to bacterial 
pathogens, specifically S. pneumoniae,  since the introduction of heptavalent 
pneumococcal vaccine (PCV-7) licensed in 2000 6, 9,  S. pneumoniae still causes 17,000 
cases annually of invasive disease in children under 5 years old in the U.S. which results 
in about 200 fatalities 6. In addition more resistant strains of bacterial pneumonia 
continue to pose a problem especially as more antibiotics are introduced into the 
community to treat these bacterial agents 12.  
1.4 DIAGNOSTICS 
 Determining the etiology of pneumonia for children is difficult in practice. Less 
than 10% of children with pneumonia have live bacteria present in the blood stream, 
limiting the effectiveness of blood cultures as a diagnostic. In addition the majority of 
children do not produce enough sputum to test, “and there are no definitive tests that are 
noninvasive and accurate” 4, 10, 12. For instance, testing bacterial antigens generally lacks 
sensitivity and specificity, and bacterial antibodies in children are “either absent (in the 
case of nontypable H. influenzae and Moraxella catarrhalis) or severely limited (S. 
pneumoniae)” 4. Invasive procedures such as lung punctures or thoracentesis where fluid 
or air is removed from the pleural space in the lung are reserved for very severe cases of 
pneumonia. The definitive determination of the etiology of pediatric pneumonia is 
generally reserved for children who are hospitalized with a severe case of pneumonia 
who are not responding to empirical therapy 10. For the majority of pediatric CAP 
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patients, clinicians diagnose patients based on their symptoms and their chest radiography 
findings 4.  
 Chest radiography determines the presence and “the location of a pulmonary 
infiltrate in all children with suspected CAP evaluated in the emergency department as 
well as those requiring hospitalization” 1. It is important to note that chest radiographs do 
not distinguish between viral or bacterial pathogens 4. Even though the intraobserver 
agreement for pediatric radiologists in detecting presence or absence of pneumonia was 
found to be good (Kappa statistic=0.87; 95% CI 0.60-0.99), the interobserver agreement 
for pediatric radiologists was less convincing (kappa=0.51, 95% CI: 0.39-0.64) 14. These 
results suggest that chest radiographs cannot be used exclusively in determining care of 
for pediatric pneumonia patients. The resulting care for these patients is largely 
determined by the clinical manifestations of the disease and the subsequent decisions 
made by the attending physician. 
 The clinical presentation of pneumonia includes dyspnea, shallow or grunting 
respirations, “the sudden onset of fever, cough, and tachypnea [abnormally fast 
breathing]” 1, 9.  The distinction between a viral and bacterial pathogen-causing 
pneumonia can be less evident upon examination. Bacterial pneumonia is characterized 
by tachypnea, crackling noises and hard breathing heard upon physical examination1. 
Viral pneumonia is suspected when wheezing is present, but children with asthma but not 
viral pneumonia may present with similar symptoms thereby masking the true etiology of 
the pneumonia 1, 12.   
 Patients with asthma receive different empiric therapy than patient without asthma 
possibly because of this difficult separation of asthma-related symptoms and pneumonia-
6 
related symptoms. Recently different phenotypes and risk factors have been shown to be 
associated with three different “types” of wheezing in children between ages 2-6 years 
old has been found. The first type “early wheezing” is defined as having been diagnosed 
with one lower respiratory tract infection (LRTI) with presentation of wheezing in the 
first 2 years of life and having no wheezing in the previous 12 months,  the second type is 
“persistent wheezing” which is defined as one LRTI with wheezing in the first 2 years of 
life and presenting with wheezing in the past 12 months, and the third type is labeled 
“late onset wheezing” which is defined as no LRTI during the first 2 years of life and 
wheezing present in the last 12 months15. The fact that the risk factors are different for 
the three types of wheezing (e.g. maternal asthma being a substantial risk factor for 
children with persistent wheezing, but less so for the other types)15, could be due to 
different etiologies that caused their initial LRTI, further confounding the relationship 
between asthma, wheezing and pneumonia even further. Once CAP is diagnosed and the 
pathogen is suspected to be bacterial, either typical or atypical, empiric therapy is 
administered. 
1.5 TREATMENT 
 Currently there are no official national guidelines in the United States for 
prescribing empiric therapy for CAP, however some antibiotics are more commonly 
recommended by various organizations, such as the World Health Organization (WHO) 
and the British Thoracic Society (BTS) (Table 1) 1, 4, 16. Typically penicillin derivatives 
(e.g. ampicillin, amoxicillin, or penicillin) which are part of the beta-lactam class (which 
also include cephalosporins, such as cefuroxime, ceftriaxone, and ceftaxime), are 
considered to be the best first line therapy for CAP as it is highly effective against S. 
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pneumoniae, the most likely pathogen 6. Macrolides such as azithromycin, 
clarithromycin, or erythromycin, are generally recommended in addition to a beta-lactam 
to treat patient who present with wheezing, a sign of an atypical infection.  Broad 
spectrum antibiotic coverage, such as beta-lactam and macrolide combination therapy, 
risks exposing the patient to additional toxic drug effects and increases the risk for 
antibiotic resistance in the community. Although beta-lactam monotherapy and in certain 
cases beta-lactam and macrolide combination therapy are recommended across published 
guidelines, the amount and quality of evidence to support these recommendations in 
children with CAP is limited5. 
 Few comparative effectiveness studies have been done specifically in children. 
These studies generally have found no statistical difference in length of stay or clinical 
failure between the use of beta-lactam monotherapy and beta-lactam and macrolide 
combination therapy however may be underpowered to find a true difference in outcomes 
(Table 2). These studies range from 116 to 893 patients. Stratification by therapy reduces 
the numbers to as few as 24 patients per therapy group. In addition to small sample sizes, 
these studies also vary in the characteristics of their study populations, including age, 
ambulatory versus outpatient settings, and even country of origin.  
 There are significantly more comparative effectiveness studies done in the adult 
population and many time clinicians review the results from these studies to guide 
empiric prescribing in children. There is much less agreement between studies in the 
adult population (Table 2).  While some studies have found a decrease in 30 day 
mortality when treating patients with beta-lactam and macrolide combination therapy 
when compared to beta-lactam monotherapy, others have not 17-22. These varying results 
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in adults could be due to the heterogeneity of inclusion criteria among the various studies, 
including differences in patient age, study setting (i.e., community- or long-term care 
facility-dwelling), and presence of comorbid conditions. Although these studies are used 
to inform prescribing practices in children, they are not directly generalizable to the 
pediatric population. It is also unknown the degree to which empirically selecting 
antibiotic and the side effects of the antibiotics affect the clinical outcome of children 
with pneumonia 1. 
 There are side effects to all antibiotic therapies, judiciously prescribed or not, 
which vary in severity and can include “anaphylaxis, organ toxicity, serum sickness, 
Stevens Johnson syndrome [a serious disorder where the skin and mucous membranes of 
the patient develop a painful rash that spreads and blisters, killing that layer of skin], 
Clostridium difficile colitis [bacterial infection that can cause inflammation of the colon], 
and the promotion of antibiotic resistance” 6. Non-judicious prescribing of antibiotics, 
such as prescribing broad spectrum antibiotics (a beta-lactam and a macrolide) when a 
narrow spectrum antibiotic (a beta-lactam therapy alone) would be as effective, can 
increase the risk of not only antibiotic resistance, but also the financial cost to the patient 
for medications, length of stay in the hospitals, general resource utilization and likelihood 
of developing Clostridium difficile colitis11. In general it has been estimated that about 
50% of all antibiotic use is inappropriate and pathogens are becoming resistant to 
antibiotics faster than new antibiotics can be developed to target these pathogens 6. 
Currently the research agenda for Centers for Disease Control and Prevention and the 
National Institute of Allergy and Infectious Diseases is focused on developing new 
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antibiotics and promoting partnerships between physicians, health departments and 
parents to diminish the unnecessary prescribing of broad spectrum antibiotics 23.  
1.6 ANTIBIOTIC RESISTANCE 
  In the United States, hospitals create an annual antibiogram which is “a 
periodic summary of antimicrobial susceptibilities of local bacterial isolates submitted to 
the hospital’s microbiology laboratory” 24. Antibiograms are required to be done in order 
to be accredited by the Joint Commission on Accrediation of Healthcare Organizations 
(JCAHO) as a quality assurance measure 25, 26. These accredited hospitals create 
antibiograms on organisms in specimens that have been obtained at the hospital’s 
microbiology laboratory and are required to make these antibiograms available to their 
staff 27. These antibiograms are distributed to physicians within the hospital to aid them 
in their choice of empiric antibiotic therapy as well as to aid the hospitals in tracking 
trends of antibiotic resistance over time.  
 The antibiograms report the minimum inhibitory concentration (MIC) for each 
drug and organism combination. MIC “is the lowest concentration of drug necessary to 
inhibit growth of a particular organism” 6. MIC is usually determined by putting a range 
of concentrations of a particular antibiotic (usually doses that are therapeutically 
available) on each organism 28. MIC therefore determines the in vitro level of drug 
resistance for that specific organism which does not always correspond directly to the in 
vivo levels. 
 There are some antibiotics, for instance, that are still effective against organisms 
in vivo that have a high MIC in vitro (i.e. organisms that are considered resistant to the 
antibiotic). For instance, penicillin resistant S. pneumoniae has occurred due to “genetic 
10 
alterations in the affinity of S. pneumoniae  penicillin binding proteins”, but high-doses 
of penicillin, amoxicillin or ampillicin are still effective against this organism and have 
been shown to be safe to use 6. The prevalence of penicillin resistance among 
pneumococci has increased in the past decade. In adults penicillin has been shown to still 
be effective in treating nonsusceptible S. pneumoniae 29. Yu et al. suggests that in vitro 
resistance does not necessarily correlate to in vivo resistance thereby decreasing the 
necessity of using an antibiotic other than penicillin or an equivalent antibiotic in the 
beta-lactam class. If other antibiotics are being commonly used to treat CAP caused by S. 
pneumoniae then there is a greater risk that the organism will develop resistance to these 
drugs. As a consequence more nonsusceptible strains will exist and greatly limit the 
number of effective antibiotics that can be used. For instance, it has been reported that 
macrolide-resistant S. pneumoniae has increased in the past decade 30. The emerging 
resistance of S. pneumoniae to two different antibiotic classes is alarming. An important 
factor for physicians and health departments to take into account when prescribing 
antibiotics is the regional antibiotic susceptibility patterns, but it is unclear how 
antibiograms are used in hospital settings in dictating prescribing practices 31. It has been 
noted that antibiograms should not be used alone to select optimal empiric therapy as 
other individual-level patient information is needed; such as severity of the disease, 
causative agent if known, patient medical history and prior antibiotic use 24.  
1.7 CONCLUSION 
 Community-acquired pneumonia is a treatable childhood disease with several 
treatment options. The variability in treatment may exist for multiple reasons. These 
reasons include the limited number of comparative antibiotic therapy studies done in 
11 
children and the unknown effectiveness of tools, such as antibiograms, in guiding empiric 
antibiotic prescribing. Further studies are needed in these areas to standardize prescribing 
practices and to reduce broad spectrum antibiotic resistance in the community.
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TABLES 
 
 
 
Table 1: Recommended empiric therapy in published guidelines for children with 
community-acquired pneumoniaa 
 
Author or Society (Year) First-line therapy Second-line therapy 
World Health Organization  
(2009) 
Amoxicillin Amoxicillin-clavulanic acid 
with or without macrolide 
South African Thoracic 
Society 
(2005) 
Amoxicillin, Ampicillin, 
Aminoglycoside, 
Macrolide,  
Second or third generation 
cephalosporin, Amoxicillin-
clavulanic acid 
Brazilian Society of 
Pediatrics  
(2004) 
Amoxicillin, Ampicillin, 
penicillin, second or third 
generation cephalosporin 
Amoxicillin-clavulanic 
acid, macrolide 
Canadian Medical 
Association (1997) 
Amoxicillin, Macrolide, 
second generation 
cephalosporin 
Third generation 
cephalosporin 
a Table modified from Nascimento-Carvalho, CM.16 
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Table 2: Summary of epidemiologic studies of empiric antibiotic therapy in patients with community-acquired pneumonia 
 
Author 
(Year) 
Patient 
Population 
Study 
Design 
Number of 
Patients 
Antibiotic 
Exposure 
Outcome 
Measurement 
Main Conclusion 
Kogan et al. 
(2003)32 
Children 
(1mo-14 
years) 
Pakistan 
Randomized 
Control 
Trial 
47 
Bacterial 
Pneumonia 
 
59 
Atypical 
bacterial 
pneumonia 
Bacterial: 
azithromycin 
(n=23) or 
amoxicillin (n=24) 
 
Atypical: 
azithromycin 
(n=33)  or 
erythromycin 
(n=26) 
No fever or 
improvement 
of 75% or 
more on X-
ray 
examination 
on day 7 
1.Azithromycin and amoxicillin 
behaved similarly in cases with 
bacterial pneumonia, both had 100% 
clearage on x-ray at day 14 
 
2. Azithromycin and amoxicillin 
behaved similarly in atypical 
bacterial cases except azithromycin 
had slightly better clearage on x-ray 
at day 14 (100% vs. 81%, p-value 
0.059) 
 
Aurangzeb 
et al.  
(2003)33 
 
Children 
(3mos-6 
years) 
Chile 
Randomized 
Control 
Trial 
124 
children 
Amoxicillin 
(n=43) cefuroxime 
(n=41) 
clarithromycin 
(n=42) 
Clinical 
outcome: no 
clinical 
improvement 
after 48 hours 
of treatment 
 
LOS 
 1. Amoxicillin was found to be the 
most cost effective in treating non-
severe and severe CAP. 
 
2. No statistical difference in median 
LOS (3 days) or in clinical outcome 
between the three therapies. 
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Table 2 (continued): Summary of epidemiologic studies of empiric antibiotic therapy in patients with community-acquired pneumonia 
 
Author 
(Year) 
Patient 
Population 
Study 
Design 
Number of 
Patients 
Antibiotic 
Exposure 
Outcome 
Measurement 
Main Conclusion 
Zhang et al.  
(2008)34 
Children 
(29 days-
12 years) 
Brazil 
Retrospectiv
e Cohort 
893 
children  
Penicillin, 
cephalosporin and 
“other” 
monotherapies 
 
Combination 
therapy (unclear 
what antibiotics 
this includes) 
Antibiotic 
failure (initial 
antibiotic was 
changed 72 
hours or more 
after no 
clinical 
improvement 
was shown) 
 
LOS 
1. In an unadjusted comparison, 
empiric antibiotic therapy failed in 
43 cases or 4.8%.  
 
2. No statistically significant 
difference in mean LOS  (p-
value=0.08) 
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Table 2 (continued): Summary of epidemiologic studies of empiric antibiotic therapy in patients with community-acquired pneumonia 
 
Author 
(Year) 
Patient 
Population 
Study 
Design 
Number of 
Patients 
Antibiotic 
Exposure 
Outcome 
Measurement 
Main Conclusion 
Gleason et 
al. (1999)22 
Adults  
(≥65 years 
old) 
Medicare 
patients in 
US 
Retrospectiv
e Cohort 
9751 
communit
y-dwelling 
adults 
 
3194 long-
term 
facility 
adults 
Penicillin, 1st, 2nd, 
3rd-generation 
cephalosporin, 
macrolides, and 
fluroquinolones 
30 day 
mortality 
 
30 day 
readmission 
 
LOS 
1. 77% higher likelihood of 30 d 
mortality when treated with a beta-
lactam and macrolide combination 
therapy compared to a non-
pseudonomal 3rd-generation 
cephalosporin, but beta-lactam alone 
not associated with greater mortality 
 
2. No regimen was independently 
associated with decreased 
rehospitalization, and only 
aminoglycoside plus another agent 
was associated with an increased 
rehospitalization rate. 
 
3. No regimen was significantly 
associated with a shorter LOS 
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Table 2 (continued): Summary of epidemiologic studies of empiric antibiotic therapy in patients with community-acquired pneumonia 
 
Author 
(Year) 
Patient 
Population 
Study 
Design 
Number of 
Patients 
Antibiotic 
Exposure 
Outcome 
Measurement 
Main Conclusion 
Dudas et al. 
(2000)20 
Children 
and adults  
(1-105 
years old) 
AmeriNet 
patients in 
US  
Prospective 
Cohort 
2963  Non-severe CAP: 
2nd or 3rd-
generation 
cephalosporin or 
beta-lactam with or 
without macrolide 
 
Severe CAP in 
ICU: Macrolide 
and 3rd generation 
cephalosporin with 
antipseudonomal 
activity 
Mortality 
 
LOS 
1. Patients who received 2nd or 3rd 
generation cephalosporin 
monotherapy or beta-lactam with a 
macrolide are independently 
associated with a decreased 
probability of mortality. (OR: 0.4; 
95% CI: 0.2 to 0.8) 
 
2. Patients who received 2nd or 3rd 
generation cephalosporin 
monotherapy or beta-lactam with a 
macrolide are independently 
associated with a decreased LOS (p-
value: 0.0003).  
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Table 2 (continued): Summary of epidemiologic studies of empiric antibiotic therapy in patients with community-acquired pneumonia 
 
Author 
(Year) 
Patient 
Population 
Study 
Design 
Number of 
Patients 
Antibiotic 
Exposure 
Outcome 
Measurement 
Main Conclusion 
Houck et al. 
(2001)19 
Adults 
(≥ 65 years 
old) 
Medicare, 
US 
Retrospectiv
e Cohort 
10,069 1. Monotherapy 
with beta-lactam 
(2nd, 3rd, 4th 
cephalosporin) 
2. Macrolide 
monotherapy 
3. Fluroquinolone 
monotherapy 
4. Fluroquinolone 
+ beta-lactam 
combination 
therapy 
5. Any other 
antibiotic 
6. beta-lactam + 
macrolide 
combination 
therapy 
30 day 
mortality 
1. No statistical difference in 30 d 
mortality between patients who 
received beta-lactam and macrolide 
combination therapy to patients who 
received beta-lactam monotherapy in 
the adjusted model.  
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Table 2 (continued): Summary of epidemiologic studies of empiric antibiotic therapy in patients with community-acquired pneumonia 
 
Author 
(Year) 
Patient 
Population 
Study 
Design 
Number of 
Patients 
Antibiotic 
Exposure 
Outcome 
Measurement 
Main Conclusion 
Brown et al. 
(2003)21 
Adults  
(> 18 
years) 
HBSI 
database, 
US 
Retrospectiv
e Cohort 
44814  25,996 received 
monotherapy 
(ceftriaxone, 
macrolides, 
fluorinated 
quinolones, other 
cephalosporins, 
penicillin) 
 
18,818 received 
dual therapy 
(ceftriaxone + 
macrolide, 
fluorinated 
quinolones + 
macrolide, other 
cephalosporins + 
macrolide, 
penicillin + 
macrolide) 
LOS 
 
Cost of 
hospital 
charges 
 
30 day 
mortality rate 
1. Penicillin was statistically similar 
in LOS for monotherapy and dual 
therapy.  
 
2. Increased 30 day mortality in  
patient who received penicillin 
monotherapy compared to dual 
therapy. 
 
3. Ceftriaxone and macrolide 
generally had shortest LOS, lowest 
hospital charges, and no statistical 
difference in 30 day mortality. 
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Table 2 (continued): Summary of epidemiologic studies of empiric antibiotic therapy in patients with community-acquired pneumonia 
 
Author 
(Year) 
Patient 
Population 
Study 
Design 
Number of 
Patients 
Antibiotic 
Exposure 
Outcome 
Measurement 
Main Conclusion 
Lodise et al.  
(2007)18 
Adults  
(≥ 65 years 
old) 
Veterans 
Integrated 
Services 
Network 2, 
US 
Retrospectiv
e Cohort 
515 Extended beta-
lactam 
monotherapy 
 
Extended beta-
lactam and 
macrolide 
combination 
therapy 
14 day 
mortality 
 
30 day 
mortality 
1. No statistical difference in 
mortality at either 14 day or 30 day 
between monotherapy and dual 
therapy in patients who had a PSI of 
IV or lower (i.e. non severe 
pneumonia).  
 
2. Combination therapy significantly 
reduced 14 day and 30 day mortality 
in patients who had a PSI class of V 
(i.e. severe pneumonia).  
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Table 2 (continued): Summary of epidemiologic studies of empiric antibiotic therapy in patients with community-acquired pneumonia 
 
Author 
(Year) 
Patient 
Population 
Study 
Design 
Number of 
Patients 
Antibiotic 
Exposure 
Outcome 
Measurement 
Main Conclusion 
Bratzler et 
al. 
(2008)17 
Adults 
(≥ 65 years 
old) 
Medicare, 
US 
 
Retrospectiv
e Cohort 
27,730 1. Macrolide 
2. Fluoroquinolone 
3. beta-lactam 
4. 
Aminoglycosides 
5. 2nd generation 
cephalosporin 
6. 3rd generation 
cephalosporin 
7. Other 
8. Macrolide and 
Cephalosporin 
9. Fluoroquinolone 
and Cephalosporin 
10. Macrolide and 
beta-lactam 
30 day 
mortality 
 
1. Fluoroquinolone monotherapy and 
cephalosporin plus a macrolide 
combination therapy significantly 
decreased 30d mortality in patients 
with severe pneumonia (PSI class IV 
or V). 
 
2. No statistical difference in 30 d 
mortality in non-severe pneumonia 
cases, regardless of empiric therapy. 
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2.1 ABSTRACT 
Objective: To determine the comparative effectiveness of beta-lactam monotherapy and 
beta-lactam and macrolide combination therapy on clinical outcomes in the treatment of 
children hospitalized with community-acquired pneumonia (CAP).  
Methods: A retrospective cohort study was conducted using the Pediatric Health 
Information System (PHIS) database during 2006-2008.  Associations between empiric 
antibiotic therapy and hospital readmission for the same episode of pneumonia were 
estimated using logistic regression. Associations between empiric antibiotic therapy and 
length of hospital stay were estimated using a negative binomial generalized estimating 
equation. Potential confounders such as age, principal payer, asthma status, and severity 
of illness were considered.   
Results: There were 20,743 patients hospitalized with CAP. Of these, 24% received beta-
lactam and macrolide combination therapy upon admission. Compared to children who 
received beta-lactam monotherapy, children who received beta-lactam and macrolide 
combination therapy were 20% less likely to stay in the hospital an additional day (RR: 
0.80; 95% CI: 0.75, 0.86) but did not have a different readmission rate (RR: 0.68; 95% 
CI: 0.42, 1.09). The effect of combination treatment on reducing LOS is stronger with 
increasing patient age.  
Conclusion: Patients hospitalized with CAP who receive beta-lactam and macrolide 
combination therapy have a shorter length of stay and similar rates of readmission when 
compared to patients who receive beta-lactam monotherapy.  
23 
 
2.2 INTRODUCTION 
 Community-acquired pneumonia (CAP) is a common and serious infection in 
children, resulting in greater than 150,000 hospitalizations each year in the United States, 
with approximately 60,000 attributable to Streptococcus pneumoniae 2, 3. Wide variations 
in antimicrobial prescribing practices exist for children hospitalized with CAP, partially 
because the causative organism is rarely identified in clinical practice. Empiric treatment 
is therefore prescribed based on the predicted pathogens as assessed by the child’s age, 
clinical presentation upon admission, and local epidemiology of pneumonia-causing 
pathogens 6. However, the optimal empiric treatment for children hospitalized with CAP 
is not known.  
  Beta-lactam monotherapy is the recommended first-line therapy for children 
hospitalized with CAP 16, 35. Beta-lactam therapies are effective against the most common 
bacterial causes of childhood CAP, including S. pneumoniae 11. Among hospitalized 
adults and older school-aged children, macrolide therapy is sometimes added to beta-
lactam therapy in order to cover atypical pathogens such as Mycoplasma pneumoniae 27, 
36. Few studies have compared the effectiveness of beta-lactam monotherapy to beta-
lactam and macrolide combination therapy in treating CAP in the pediatric population20, 
32-34.  
 Published guidelines exist for the management of community-acquired 
pneumonia in adults; however variability in empiric therapy prescribing is still common, 
in part because studies have yielded conflicting results 22, 36. While some studies have 
found a decrease in 30 day mortality with beta-lactam and macrolide combination therapy 
compared with monotherapy, others have not 17-22. These varying results in adults could 
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be due to the heterogeneity of inclusion criteria among the various studies, including 
differences in patient age, study setting (i.e., community- or long-term care facility-
dwelling), and presence of comorbid conditions. Although these studies are used to 
inform prescribing practices in children, they are not directly generalizable to the 
pediatric population.  
 The objective of this multicenter analysis was to determine the comparative 
effectiveness of beta-lactam monotherapy compared with beta-lactam and macrolide 
combination therapy for children hospitalized with CAP. The secondary objective of this 
study was to determine the comparative effectiveness of narrow- and broad-spectrum 
antibiotic therapy. 
2.3 METHODS 
DATA SOURCE 
This retrospective cohort study used data obtained from the Pediatric Health 
Information System (PHIS). PHIS is a national administrative database containing 
resource utilization from 38 freestanding, tertiary care children’s hospitals affiliated with 
the Child Health Corporation of America (Shawnee Mission, KS). Participating hospitals 
account for 20% of all tertiary care children’s hospitals. For the purposes of external 
benchmarking, participating hospitals provide discharge data including patient 
demographics, diagnoses, and procedures. Billing data detail all of the drugs, radiologic 
imaging studies, laboratory tests, and supplies charged to each patient. Data quality and 
reliability are assured through a joint effort between Child Health Corporation of 
America and participating hospitals as previously described 37, 38. The study protocol was 
25 
 
approved by Institutional Review Boards of The Children’s Hospital of Philadelphia and 
the Drexel University College of Medicine with a waiver of informed consent. 
PARTICIPANTS 
 Children, 1-18 years of age, with CAP were eligible if they were discharged from 
any participating hospital between January 1, 2006 and December 31, 2008. Subjects 
were included if they received beta-lactam antibiotics (i.e. penicillin, 2nd and 3rd 
generation cephalosporins), alone or in combination with macrolides (i.e., erythromycin, 
clarithromycin, azithromycin) on the first day of hospitalization and if they satisfied one 
of the following International Classification of Diseases, 9th Revision (ICD-9), discharge 
diagnosis code criteria: 1) primary diagnosis of pneumonia (ICD-9 codes 481-483.8, 485-
486); 2) primary diagnosis of a pneumonia-related symptom (ICD-9 codes 780.6 or 
786.00-786.52 [except 786.1]) and a secondary diagnosis of pneumonia, empyema 
(510.0, 510.9), or pleurisy (511.0, 511.1, 511.9); or 3) primary diagnosis of empyema or 
pleurisy and a secondary diagnosis of pneumonia.  
 Children younger than one year of age were excluded because they experience a 
high rate of viral respiratory infections that are difficult to distinguish clinically from 
bacterial pneumonia. Patients with comorbid conditions that predisposed them to severe 
or recurrent pneumonia (e.g. cystic fibrosis, malignancy, sickle cell disease) were 
excluded using a previously reported classification method 39. Patients with severe illness 
at admission were also excluded as these children are likely to require broad-spectrum 
antibiotics. Severe illness was defined as intensive care admission or receipt of any one 
of the following on the first day of hospitalization: pleural fluid drainage procedure, 
vasoactive infusions (dobutamine, dopamine, epinephrine, norepinephrine), blood 
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product transfusion (packed or washed red blood cells, fresh-frozen plasma, and 
coagulation factors), invasive (endotracheal intubation) and noninvasive (continuous 
positive airway pressure) mechanical ventilation. 
PATIENT CHARACTERISTICS 
 Patient characteristics assessed included were age, sex, principal payer, and 
underlying asthma. We identified children with asthma in two ways. Asthma-related 
hospitalizations were defined by an ICD-9 code for asthma (493.0-493.2) in any 
discharge diagnosis field during any prior hospitalization in the 24 months before the 
current hospitalization. Chronic asthma controller medication use was defined by 
treatment with inhaled corticosteroids (e.g., fluticasone) or leukotriene receptor 
antagonists on the first day of hospitalization for CAP, which suggested that these 
medications were a continuation of baseline therapy. Other medications prescribed for 
asthma included beta-agonist (i.e. albuterol) therapy or systemic corticosteroids on the 
first day of their hospitalization. Systemic corticosteroids (either oral or intravenous) 
were defined by receipt of dexamethasone, hydrocortisone, methylprednisolone, 
prednisolone, or prednisone. Testing of arterial blood gases and additional radiologic 
imaging on the first day of hospitalization were included as measures of illness severity. 
Additional radiologic imaging included receiving chest computed tomography or 
ultrasound.  
TREATMENT MEASURES 
 The primary exposure of interest was empiric antibiotic therapy, classified as 
beta-lactam monotherapy or a beta-lactam plus a macrolide (i.e., combination therapy). A 
subanalysis was performed among subjects comparing individual antibiotic categories for 
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monotherapy (i.e. penicillin or aminopenicillins, 2nd generation cephalosporin or 3rd 
generation cephalosporins) and for combination therapy (i.e., penicillin or 
aminopenicillin in combination with macrolide, 2nd generation cephalosporin in 
combination with macrolide, and 3rd generation cephalosporin in combination with a 
macrolide).  
OUTCOME MEASURES 
 The main outcome measures were hospital length of stay (LOS) and readmission 
within 14 days of the index hospital discharge. LOS was defined as the discharge date 
minus the admission date. We chose 14-day readmissions because readmissions after 
initial discharge for pneumonia beyond this time frame are typically not related to 
pneumonia 40.  
DATA ANALYSIS 
 Continuous variables were described using median, range, and interquartile range 
(IQR) values and were compared across groups using the Wilcoxon rank sum test. 
Categorical variables were cross-tabulated by treatment groups and differences tested 
using the chi-square statistic.  
 Graphical analysis of LOS showed positive skew. The distribution of LOS was 
compared using Poisson and negative binomial distributions. When fit to the data, the 
negative binomial distribution had the lowest Quaslikelihood Information Criterion (QIC) 
indicating a better fit 41. Further assessment of overdispersion indicated that the true 
variance was larger than the mean, confirming overdispersion and the use of negative 
binomial regression 41-43. Because patient LOS is correlated within hospitals a generalized 
estimating equation (GEE) was used to account for this in standard error estimates. The 
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negative binomial regression model produces the log of expected counts of days stayed in 
the hospital which are used to estimate a length of stay ratio (by exponentiation of the 
beta coefficient) of >1 that indicates an association with a longer LOS on average. These 
estimates can be thought of a ratio of probability ratios of staying one more day in the 
combination therapy group compared to monotherapy.  Interaction terms between age 
and antibiotic therapy and asthma and antibiotic therapy were tested as these variables 
might modify the effect of therapy on LOS. These interaction terms remained in the final 
models if the interaction terms were statistically significant with p-value determined a 
priori of <0.05 and if their inclusion improved overall model fit (i.e. resulted in a smaller 
QIC).  
 Associations between treatment and readmission within 14 days were estimated 
using logistic regression models. Potential confounders, such as age, sex, principal payer, 
and asthma status remained in the model if their inclusion changed the effect estimate of 
the empiric therapy by greater than ≥10% 44, 45. These variables were analyzed as they 
have been previously shown to be significantly associated with empiric therapy and 
hospital LOS or hospital readmission 3, 46, 47. Interaction terms were not tested in the 
readmission models as there were few readmission events.  All statistical analyses were 
performed using SAS statistical software (version 9.2, SAS Institute Inc, Cary, N.C.). 
2.4 RESULTS 
PATIENT CHARACTERISTICS 
 A total of 20,743 patients hospitalized with CAP during the study period received 
beta-lactam therapy, alone or in combination with a macrolide. Beta-lactam monotherapy 
was given to 15,809 (76%) of children while beta-lactam and macrolide combination 
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therapy was given to the remaining 4934 (24%) children (Table 3). Patients receiving 
beta-lactam monotherapy were similar in respect to sex and prior hospitalization for 
asthma when compared with patients who received combination therapy (Table 4).  
LENGTH OF HOSPITAL STAY 
 The median LOS for the total cohort was 2 days (IQR: 2-3 days); 10% of patients 
had a LOS of 6 days or greater. The median LOS was 2 days (IQR: 2-4 days) for patients 
who received beta-lactam monotherapy and 2 days (IQR: 1-3 days; p=0.057) for patients 
who received beta-lactam and macrolide combination therapy. Results are presented for 
the unadjusted model and fully adjusted model in Table 5. In the adjusted analysis, 
patients who received combination therapy were on average 20% less likely to stay an 
additional day in the hospital when compared with patients who received monotherapy as 
empiric treatment for their episode of CAP (Table 5). No significant differences in LOS 
were found when comparing individual antibiotics among those who received 
monotherapy and individual combinations among those who received combination 
therapy (Table 5). 
 Interaction between combination therapy and age was found to be statistically 
significant (p-value <0.001). Children ages 12-18 years old who were treated with 
combination therapy were 31% less likely to stay one extra day in the hospital compared 
to children 12-18 years, who received monotherapy. Children ages 1-5 years old who 
received combination therapy were only 4% less likely to stay in the hospital one extra 
day when compared to children, 1-5 years, who received monotherapy. As shown in 
Table 6 the effect of combination therapy on reduced LOS is stronger with increasing 
patient age.  
30 
 
HOSPITAL READMISSION  
 Readmission within 14 days of index hospital discharge occurred in 0.5% of those 
who received beta-lactam monotherapy and in 0.6% of those who received beta-lactam 
and macrolide combination therapy. Odds of readmission within 14 days of index 
hospitalization were reduced among those receiving combination therapy compared with 
those receiving monotherapy; however this difference was not statistically significant 
(Table 7). A subanalysis was conducted among patients who received beta-lactam 
monotherapy as empirical treatment. In the adjusted analysis, the probability of 
readmission within 14 days of index hospitalization was not statistically different 
between patients receiving either 2nd or 3rd generation of cephalosporin when compared 
with patients receiving aminopenicillin alone (Table 7). The confidence intervals around 
the odds ratio estimated in the subanalysis were wider. This is most likely due to the 
small number of readmission events once the analysis was stratified by receipt of 
monotherapy (n=91) and may bias our results toward the null. None of the interaction 
terms tested met our criteria for inclusion in the final model.  
2.5 DISCUSSION 
 In this multicenter study, patients who received beta-lactam and macrolide 
combination therapy had a significantly shorter LOS compared with patients who 
received beta-lactam monotherapy. The magnitude of the effect for combination therapy 
in reducing LOS was greater in children ≥ 6 years old compared with children 1-5 years. 
However, among the individual therapies there was no significant difference in LOS. 
Beta-lactam and macrolide combination therapy resulted in reduced hospital readmission 
within 14 days of index discharge but the association was not statistically significant. 
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 No prior studies have compared the effectiveness of beta-lactam monotherapy to 
beta-lactam and macrolide combination therapy in children. In our study older children 
receiving combination beta-lactam and macrolide therapy had a shorter LOS compared 
with those receiving beta-lactam monotherapy. There was less of a reduction in LOS in 
younger children, ages 1-5, who received combination therapy compared with younger 
children who received monotherapy. These findings suggest a role for the addition of 
macrolide-class antibiotics in older children hospitalized with community-acquired 
pneumonia. The benefit may be explained by the higher prevalence of Mycoplasma 
pneumoniae and other atypical bacteria in older children with pneumonia 5.   
 There are two randomized, unblinded, controlled trials conducted that compared 
beta-lactam monotherapy to macrolide monotherapy 5, 32, 33. These two studies found that 
children who were treated with amoxicillin (a penicillin derivative similar to 
aminopenicillin) had similar cure rates to those children who were treated with a 
macrolide therapy 32, 33. However, both of these studies had small sample sizes (47 
children in one study32 and 87 in the other33) and it is unclear how the treatments were 
allocated 5. In one study older children were disproportionately given macrolide therapy 
32. Although these studies support the use of beta-lactam monotherapy , these studies had 
too few participants to identify specific populations or subpopulations that might benefit 
from either monotherapy or combination therapy. 
 There are several limitations to our study. First we used ICD-9 discharge 
diagnosis codes to identify study patients with pneumonia. We attempted to limit 
misclassification of a pneumonia diagnosis by using a previously validated ICD-9 coding 
algorithm 48-51. Additionally we restricted the study to those who on the first day of their 
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admission received antibiotics that are typically used to treat CAP. Our inability to 
ascribe the cause of pneumonia to a particular organism mirrors clinical practice where 
the causative organism is rarely identified.  
 Second, our adjustment for clinical characteristics of an atypical infection (e.g.,  
wheezing) used surrogate measures such as receipt of asthma therapies. Atypical bacteria, 
such as Mycoplasma pneumoniae and Chlamydophila pneumoniae, are more common in 
patients with asthma exacerbations or who present with wheezing 52. Therefore it is 
possible that the significant difference in LOS between children who received beta-
lactam monotherapy and those who received beta-lactam and macrolide combotherapy 
was due to inadequate adjustment for patients who were presumed to be infected with an 
atypical bacterium in which case the addition of a macrolide might be recommended. 
Although beta-agonists and steroid therapies are specific for treating patients with asthma 
and/or present with wheezing they may have been administered for alternate reasons in 
which case we may have underestimated the effect that beta-lactam and macrolide 
combination therapy had in treating patients with atypical bacterial pneumonia.  
 Third, despite our attempts to adjust for severity through restriction and multi-
variable adjustment, it is possible that residual confounding exists. This study was 
restricted to children who did not have factors associated with disease severity and 
complications upon admission, such as admission to the ICU, comorbid conditions, and 
receipt of a pleural fluid drainage procedure. There is currently no pneumonia severity 
index available for children therefore additional measures of disease severity were 
identified based on ICD-9 codes for discharge diagnoses, laboratory tests, procedures, 
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and radiologic imaging. It is possible that there are other measures of severity that we 
were unable to restrict or adjust for completely.  
 Finally, all participants in this study were hospitalized at a free-standing 
children’s hospital. Children typically have longer hospital stays and more expensive 
hospital stays when admitted to a children’s hospital compared with non-children’s 
hospital when controlling for primary diagnosis 53. Therefore the results from this study 
are only generalizable to pediatric populations that do not have underlying conditions in 
addition to their pneumonia diagnosis that are admitted at children’s hospitals.  
 This study is one of the only multicenter comparative effectiveness studies 
conducted in hospitalized pediatric patients with CAP in a developed country. We found 
a significant difference in LOS, but no statistical difference in hospital readmission in 
patients who received beta-lactam monotherapy and in those who received beta-lactam 
and macrolide combination therapy. These findings suggest the need for a randomized 
clinical trial comparing beta-lactam and macrolide therapies in treating children 
hospitalized with CAP to identify populations or subpopulations that benefit from 
combination antibiotic therapy.      
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Table 3: Patient characteristics by exposurea 
 
 Total 
Cohort 
(n=20743) 
Monotherap
y (n=15809) 
Combination 
Therapy 
 (n= 4934 ) 
P-
value b 
Age     
1-5 years 14672 (71) 12008 (76) 2664 (54) <0.000
1 
6-11 years 4168 (20) 2633 (17) 1535 (31)  
12-18 years 1903 (9) 1168 (7) 735 (15)  
Sex     
Male 9980 (48) 7597 (48) 2383 (48) 0.7659 
Principal Payer     
Government 10227 (49) 7936 (50) 2291 (46) <0.000
1 
Asthma     
Prior Hospitalization for 
Asthma 
2689 (13) 2024 (13) 665 (13) 0.2178 
Chronic Asthma 
Medication 
3768 (18) 2762 (17) 1006 (20) <0.000
1 
Systemic Corticosteroid 
Medication 
7020 (34) 5176 (33) 1844 (37) <0.000
1 
Beta Agonist Therapy 11371 (55) 8400 (53) 2971 (60) <0.000
1 
Other Variables for 
Degrees of Disease 
    
Arterial Blood Gases 
(ABG) 
1436 (8) 1018 (7) 418 (9) <0.000
1 
Intensive Imaging 279 (1) 198 (1) 81 (2) 0.0383 
  aUnless otherwise noted, data are expressed in counts (percentages) of patients 
  bP-value obtained via chi-square for categorical variables 
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Table 4: Empiric antibiotic therapies 
 
 
Empiric Antibiotic Therapy Number of Patients 
(%) 
Beta-lactam Monotherapy (n=15809)  
 Aminopenicillin 1977 (12) 
2nd Generation Cephalosporins 2949 (19) 
3rd Generation Cephalosporins 10833 (69) 
Beta-lactam and Macrolide Combination Therapy 
(n=4934) 
 
Aminopenicillin plus Macrolide 359 (7) 
2nd Generation Cephalosporin plus Macrolide 677 (14) 
3rd Generation Cephalosporin plus Macrolide 3898 (79) 
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Table 5: Length of stay according to empiric antibiotic therapy 
 Unadjusted RR 
(95% CI) 
Adjusted RR (95% CI) a,b,c 
Antibiotic Categories   
Monotherapy Reference Reference 
Combination Therapy 0.91 (0.87, 0.96) 0.80 (0.75, 0.86) 
Monotherapy Therapy   
Aminopenicillin Reference Reference 
2nd Generation Cephalosporin 1.06 (0.96, 1.17) 1.01 (0.91, 1.12) 
3rd Generation Cephalosporin 1.16 (1.05, 1.28) 1.03 (0.94, 1.14) 
Combination Therapy   
Aminopenicillin + Macrolide Reference Reference 
2nd Generation Cephalosporin 
+Macrolide 
1.03 (0.93, 1.15) 1.01 (0.90, 1.13) 
3rd Generation Cephalosporin + 
Macrolide 
0.88 (0.77, 1.01) 0.91 (0.79, 1.04) 
a  Results for main analysis were adjusted for age, principal payer, prior hospitalization 
for asthma, receipt of chronic asthma therapy, systemic corticosteroid medication, beta 
agonist therapy, testing for arterial blood gases, intensive imaging testing and interaction 
of therapy and age. 
b  Results for monotherapy subanalysis were adjusted for age, principal payer, prior 
hospitalization for asthma, receipt of chronic asthma therapy, systemic corticosteroid 
medication, beta agonist therapy, testing for arterial blood gases, and intensive imaging 
testing. 
c Results for combination therapy subanalysis were adjusted for age, principal payer, 
prior hospitalization for asthma, receipt of chronic asthma therapy, systemic 
corticosteroid medication, beta agonist therapy, testing for arterial blood gases, and 
intensive imaging testing. 
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Table 6: Interaction effect of age and empiric antibiotic therapy on LOS 
 
Age Category Adjusted RR (95% CI) a,b 
 
1-5 years 0.96 (0.86, 1.06) 
 
6-11 years 0.85 (0.79, 0.91) 
 
12-18 years 0.69 (0.49, 0.98) 
 
a Results are for patients who received combination therapy with monotherapy as the 
reference category 
b Results are adjusted for principal payer, prior hospitalization for asthma, receipt of 
chronic asthma therapy, systemic corticosteroid medication, beta agonist therapy, testing 
for arterial blood gases, intensive imaging testing
38 
 
 
 
 
Table 7: Readmission within 14 days of index hospitalization according to empiric 
antibiotic therapy 
 Unadjusted OR 
(95% CI) 
Adjusted OR (95% CI) a, b 
Antibiotic Categories    
Monotherapy Reference Reference 
Combination Therapy 0.77 (0.49, 1.23) 0.68 (0.42, 1.09) 
Monotherapy   
Aminopenicillin Reference Reference 
2nd Generation 
Cephalosporin 
1.27 (0.73, 2.23) 1.68 (0.93, 3.01) 
3rd Generation 
Cephalosporin 
1.07 (0.70, 1.63) 1.31 (0.84, 2.06) 
a Results for main analysis were adjusted for age   
b Results for monotherapy subanalysis were adjusted for age, and testing for arterial blood 
gases  
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3.1 ABSTRACT 
Objective: A multi-level, random intercept, logistic regression was used to explain the 
influence of hospital-level pneumococcal penicillin non-susceptibility patterns on 
individual-level antibiotic prescription using data from 33 children’s hospitals.  
Patients and Methods :  A multi-level cross-sectional study  in 33 children’s hospitals, 
among children, 1-18 years of age, with CAP discharged in 2006. Hospital-level 
antibiotic susceptibility data was collected from surveys and patient-level data was 
obtained from an administrative database. The primary exposure was the proportion of 
penicillin non-susceptible pneumococcal isolates reported by each hospital. A secondary 
exposure included using the proportion of penicillin-resistant pneumococcal isolates to 
determine if a threshold of susceptibility existed. Receipt of narrow spectrum empiric 
antibiotic therapy (i.e., penicillins or aminopenicillins) was the main outcome measure.  
Results: 5,033 children diagnosed with community-acquired pneumonia (CAP) were 
eligible. The proportion of penicillin non-susceptible isolates ranged from 9%-70% 
across hospitals while the proportion of penicillin resistant isolates ranged from 0%-60%. 
Narrow spectrum antibiotics were prescribed to 7% of patients; 41% of patients received 
cephalosporin class antibiotics alone. There was no significant association between the 
proportion of penicillin nonsusceptible pneumococcal isolates at individual hospitals and 
narrow spectrum prescribing. However, every 10% increase in penicillin-resistant 
pneumococcal isolates was associated with a 28% decrease in narrow spectrum antibiotic 
prescribing (adjusted odds ratio, 0.72; 95% confidence interval: 0.56-0.88). 
Conclusion: There was substantial variability in empiric antibiotic prescribing for CAP 
among children’s hospitals in the U.S. High- (i.e., resistant) but not modest-levels (i.e., 
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intermediate susceptibility) of penicillin resistance were associated with broad spectrum 
antibiotic prescribing.  
42 
 
3.2 INTRODUCTION 
 Antibiotic resistance is a major public health problem. Infections caused by drug-
resistant bacteria lead to worse clinical outcomes than infections caused by susceptible 
bacteria 54. Furthermore, the rise of antibiotic resistant organisms has rapidly limited the 
availability of effective therapies for some infections 54. Therefore, reducing antibiotic 
resistance is a major focus of many national and international organizations 23, 54, 55.  
Improving antibiotic prescribing practices is an important part of the global strategy to 
reduce antibiotic resistance. Studies aimed at improving antibiotic prescribing, including 
encouraging narrower spectrum antibiotic prescribing, have traditionally focused on 
persuasive (e.g., educational) or restrictive (e.g., formulary restriction) interventions 56. 
These approaches, while often successful, yield only modest improvements in prescribing 
practices.  
 Hospital “antibiograms,” bacteria-specific antimicrobial susceptibility profiles, 
are often used to support the need for improving antibiotic prescribing practices. 
However, antibiograms may also be used to influence antibiotic prescribing 57. 
Antibiograms are disseminated to physicians by hospitals at varying intervals, though 
usually at the end of each calendar year. These antibiograms are based on Clinical and 
Laboratory Standards Institute (CLSI ) breakpoints,58 the minimum inhibitory 
concentration (MIC) cut-off values that determine the level at which an organism is 
susceptible to specific antibiotics. The categories, susceptible, intermediate, and resistant, 
correspond to the likelihood of successful or unsuccessful in vitro inhibition of bacterial 
growth 58, 59. Physicians use antibiograms to guide empiric prescribing of broad spectrum 
antibiotics for common infections. In some cases, breakpoints are altered to better align 
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with clinical outcomes. For example, the CLSI changed the breakpoints for Streptococcus 
pneumoniae, the most common bacterial cause of community-acquired pneumonia 
(CAP), in 2008 after studies demonstrated that narrow spectrum antibiotics, such as 
penicillin and aminopenicillins, were effective in treating non-central nervous system 
(CNS) pneumococcal infections even when classified as non-susceptible in vitro 59. The 
proportion of pneumococcal isolates now reported as “susceptible” to penicillin has 
increased as a result of the change, however, the impact of hospital antibiograms on 
antibiotic prescribing for community-acquired infections is not known.  
 The aim of this multicenter study was to determine the association between 
pneumococcal penicillin susceptibility testing results, as reported by hospital 
antibiograms, and physicians’ prescribing practices for children hospitalized with CAP. 
We used antibiograms incorporating 2005 pneumococcal susceptibility patterns, as these 
antibiograms would be available to physicians when prescribing antibiotics for CAP in 
2006.  
3.3 METHODS 
STUDY DESIGN AND DATA SOURCES 
 This multi-level cross-sectional study used hospital-level data collected from 
surveys and patient-level data obtained from an administrative database. The Pediatric 
Health Information System (PHIS) was used to identify hospitals that contributed group-
level data and was used to gather prescribing information for patient-level data. PHIS is a 
national administrative database containing resource utilization from 38 freestanding, 
tertiary care children’s hospitals affiliated with the Child Health Corporation of America 
(Shawnee Mission, KS). Participating hospitals account for 20% of all tertiary care 
44 
 
children’s hospitals. For the purposes of external benchmarking, participating hospitals 
provide discharge data including patient demographics, diagnoses, and procedures. 
Billing data detail all of the drugs, radiologic imaging studies, laboratory tests, and 
supplies charged to each patient. Data quality and reliability are assured through a joint 
effort between Child Health Corporation of America and participating hospitals as 
previously described 37, 38. The study protocol was approved by Institutional Review 
Boards of The Children’s Hospital of Philadelphia and the Drexel University College of 
Medicine. 
Group-level Data. Hospital-level antibiotic susceptibility patterns for S. pneumoniae 
were determined via written surveys sent to the microbiology laboratories of each 
hospital. The surveys requested information regarding antibiotic susceptibility patterns 
for pneumococcal isolates tested in 2005 in aggregate and, when available, by specific 
site (i.e., blood isolates, respiratory isolates). The cutpoints were defined using MICs for 
S. pneumoniae susceptibility as established by the CLSI for 2005 as follows: <0.06 
mcg/mL, susceptible; 0.12-1.0 mcg/mL, intermediate; and >2.0 mcg/mL, resistant9. An 
isolate was considered non-susceptible if it was classified as either intermediate or 
resistant.  
Individual-level Data. Patient-level information for the calendar year 2006 was retrieved 
from the PHIS database. Children, 1-18 years of age, with CAP were eligible if they were 
discharged from any participating hospital between January 1 and December 31, 2006. 
Subjects were included if they received antibiotic therapy on the first day of 
hospitalization and if they satisfied one of the following International Classification of 
Diseases, 9th Revision (ICD-9), discharge diagnosis code criteria: 1) Primary diagnosis of 
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pneumonia (ICD-9 codes 481-483.8, 485-486); 2) Primary diagnosis of a pneumonia-
related symptom (ICD-9 codes 780.6 or 786.00-786.52 [except 786.1]) and a secondary 
diagnosis of pneumonia, empyema (510.0, 510.9), or pleurisy (511.0, 511.1, 511.9); or 3) 
Primary diagnosis of empyema or pleurisy and a secondary diagnosis of pneumonia. 
Only patients receiving antibiotics considered conventional treatment for childhood CAP 
(i.e. penicillin, macrolide, cephalosporin, vancomycin, and clindamycin) on the first day 
of hospitalization were included.  
 We identified children with asthma in two ways. Asthma-related hospitalizations 
were defined by an ICD-9 code for asthma (493.0-493.2) in any discharge diagnosis field 
during any prior hospitalization in the 24 months before the current hospitalization. 
Chronic asthma controller medication use was defined by treatment with inhaled 
corticosteroids (e.g., fluticasone) or leukotriene receptor antagonists on the first day of 
hospitalization for CAP, which suggested that these medications were a continuation of 
baseline therapy.  
 Data from five of the thirty-eight hospitals were excluded because of incomplete 
patient-level information (n=3) or an incomplete antibiogram was returned (n=2). 
Children younger than one year of age were excluded because they experience a high rate 
of viral respiratory infections that are difficult to distinguish clinically from bacterial 
pneumonia. Patients with comorbid conditions that predisposed them to severe or 
recurrent pneumonia (e.g. cystic fibrosis, malignancy, sickle cell disease) were excluded 
using a previously reported classification scheme 39.  
MEASURED EXPOSURES 
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 The primary exposure of interest was the proportion of penicillin non-susceptible 
pneumococcal isolates reported by each hospital. Secondary exposures included using the 
proportion of penicillin-resistant pneumococcal isolates to determine if a threshold of 
susceptibility existed, as well as restricting the exposures to blood or respiratory 
penicillin non-susceptible pneumococcal isolates as these isolates were more likely than 
aggregated isolates to represent invasive disease.  
MEASURED OUTCOMES 
 The primary outcome was the receipt of empiric narrow spectrum antibiotic 
therapy (i.e., penicillin or aminopenicillins).  
DATA ANALYSIS 
 Categorical variables were described using frequencies and percentages. Chi-
square analysis was used to compare the between hospital distribution of individual level 
variables. 
 We used multi-level, random intercept, logistic regression to explain the influence 
of hospital-level penicillin non-susceptible pneumococcal patterns on individual-level 
antibiotic prescription for several reasons. First, the observations are not independent as 
patients admitted to the same hospital are similar in regards to both their exposure and 
outcome, precluding a simple logistic regression (rather than multi-level) modeling 
approach. Second, the variability within and between hospitals in the PHIS database is of 
interest and a generalized estimating equation (GEE) (rather than random effects) 
approach would treat the heterogeneous patient population in each hospital as a nuisance 
factor 60. Third, the inference with a random-effects model is made for a specific patient 
in a specific hospital while the inference with a GEE approach results in a population 
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effect averaged over all the hospitals. The population average inference of the GEE 
approach does not allow for interpretation of the influence from the complex 
heterogeneities that exist between hospitals 61, 62.  
 The first model, considered the ‘empty’ model, contained the random-intercept 
only and no other predictor variables. This model accounted for the probability of 
receiving penicillin or aminopenicillin alone only as a function of which hospital the 
patient attended. The second model, an extension of the ‘empty’ model, added the 
proportion of penicillin non-susceptible pneumococcal isolates. The proportion of 
penicillin non-susceptible pneumococcal isolates was grand-mean centered at 52% 
(standard deviation [SD]: 11.4) 63. This model determined the amount of variance 
explained by the addition of susceptibility patterns reported from each hospital. In the 
additional sub-analyses, the exposures were grand-mean centered at 26% (SD: 15.1) for 
penicillin-resistant S. pneumoniae, 43% (SD: 15.3) for penicillin-nonsusceptible S. 
pneumoniae blood isolates, and 54% (SD: 13.9) for penicillin nonsusceptible S. 
pneumoniae respiratory isolates.  
  The third model tested individually the inclusion of potential effect modifiers, 
age and asthma status. These interaction terms, determined a priori, remained in the 
model if the main effect of non-susceptible pneumococcal patterns and aminopenicillin 
prescribing changed by 10% or more 64. The models were compared using Akaike’s 
information criterion (AIC) 65. The model with the smallest AIC was chosen. Other 
variables describing the severity of illness (e.g. empyema) were not considered as either 
confounders or effect modifiers, as severity of illness for CAP rather than hospital-
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reported antibiotic susceptibility patterns likely determine broad spectrum antibiotic 
prescribing 11. 
 The median odds ratio (OR) was calculated to quantify the heterogeneity between 
different hospitals. The median OR, calculated using the variance of the hospitals in each 
model, is the median value of the ORs when comparing all possible pairs of patients with 
similar covariates admitted to different hospitals 66, 67. A median OR equal to 1 indicates 
that there is no difference between hospitals in the probability of receiving narrow 
spectrum antibiotics and a median OR larger than 1 indicates large variation in the 
probability of receiving narrow spectrum antibiotics between hospitals. This measure is 
not dependent on the prevalence of narrow spectrum antibiotic prescribing and can 
therefore be compared with future studies. All statistical analyses were performed using 
SAS statistical software (version 9.2, SAS Institute Inc, Cary, N.C.). 
3.4 RESULTS 
HOSPITAL-LEVEL EXPOSURE 
Hospitals reported the percentage of pneumococcal isolates tested in 2005 that were 
susceptible to penicillin, overall and, when available, by specific site (i.e., blood isolates, 
respiratory isolates) (Table 8). 
PATIENT CHARACTERISTICS 
There were 5,033 patients from 33 hospitals. The median age of this cohort was 3 years 
(interquartile range: 2-7). Narrow spectrum antibiotic therapy was prescribed to 349 (7%) 
of the 5,033 children with CAP. Patients who received a narrow spectrum antibiotic were 
younger and more likely to have a prior asthma-related hospitalization than those 
receiving empiric broad spectrum antibiotic therapies (Table 9).   
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VARIABILITY IN ANTIBIOTIC PRESCRIBING 
Commonly used antibiotics were classified into 7 categories based on their spectrum of 
antibacterial activity to describe hospital-level variability in antibiotic prescribing 
(Figure 1). Overall, 41% (n=2224) of all the patients received cephalosporins as empiric 
therapy for CAP; cephalosporins were also the most commonly prescribed antibiotic 
within each hospital. One exception was a hospital where penicillins or aminopenicillins 
alone were prescribed at a much higher rate, 57%, compared with other hospitals, in 
which penicillins or aminopenicillin alone accounted for 6% of the total proportion of 
antibiotics prescribed for CAP during the study period.  
ASSOCIATION OF RESISTANCE AND PRESCRIBING 
In the adjusted analysis there was no association between the proportion of penicillin-
non-susceptible pneumococcal isolates and narrow spectrum antibiotic prescribing, either 
overall or when restricted to blood or respiratory isolates (Table 10). However, the 
association between the proportion of penicillin-resistant pneumococcal isolates and 
narrow spectrum antibiotic prescribing was significant; patients were 28% less likely to 
receive narrow spectrum antibiotics for every 10% increase in penicillin-resistant 
pneumococcal isolates (Table 10). The interaction effects did not meet the inclusion 
criteria and, therefore, were not included in the final models. 
 One of the hospitals was unique in its prescribing practices (Figure 1) and its 
inclusion increased the variance component in the models. There was no association 
between proportion of penicillin non-susceptible S. pneumoniae isolates and narrow 
spectrum prescribing when this hospital was excluded (adjusted OR: 0.94; 95 % 
confidence interval: 0.73, 1.21) but the overall fit of the model improved (AIC with the 
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outlier was 2171.8 versus 2011.1 without the outlier). This finding indicates that some, 
but not all, of the variability between hospitals is due to this hospital which had a 
disproportionate amount of narrow spectrum antibiotic prescribing.  
 The median OR for penicillin non-susceptible isolates, overall and site-specific, 
indicated large variability between hospitals in narrow spectrum prescribing (Table 11). 
In contrast, there was much less variability between hospitals in the probability of 
prescribing narrow spectrum antibiotics when adjusting for penicillin-resistant 
pneumococcal isolates; on average a patient had 1.62 higher odds of receiving a narrow 
spectrum antibiotic solely based on which hospital they were admitted. By comparing the 
median OR of the different models it can be deduced that the variability in prescribing 
practices between hospitals decreases significantly when adjusting for the proportion of 
penicillin-resistant S. pneumoniae isolates. 
3.5 DISCUSSION 
 This multicenter study found substantial variability in empiric antibiotic 
prescribing for CAP among children’s hospitals in the U.S. High- (i.e., resistant) but not 
modest-levels (i.e., intermediate susceptibility) of penicillin resistance were associated 
with broad spectrum antibiotic prescribing. As narrow spectrum antibiotics effectively 
treat most non-CNS pneumococcal infections, our findings suggest that strategies to 
optimally align antibiotic susceptibility patterns and clinical outcomes can lead to 
meaningful decreases in broad spectrum antibiotic prescribing.  
 The degree of variability in empiric therapy prescribing for CAP in this study is 
similar to prior studies investigating general antibiotic prescribing 68.  In our study, broad 
spectrum antibiotics were more commonly prescribed as empiric therapy for CAP than 
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narrow spectrum antibiotics, such as penicillin. This is in contrast to recommended first 
line therapy for a child who is hospitalized with CAP, even in hospitals with reported 
penicillin non-susceptible S. pneumoniae 69. Studies in adults29 and children70 
demonstrated that in vitro resistance did not correlate with in vivo resistance for non-CNS 
pneumococcal infections, thereby decreasing the necessity of using an antibiotic other 
than penicillin. Findings such as these informed the CLSI decision to change the 
breakpoints in 2008 to better mirror the clinical effectiveness of penicillin for non-CNS 
pneumococcal infections 71. Our study supports the rationale behind the decision of the 
CLSI, as we found an association between penicillin resistance and penicillin prescribing.  
 The Centers for Disease Control and Prevention reported that the number of non-
meningitis pneumococcal isolates categorized as resistant decreased from 10.3% to 1.2% 
using the 2008 CLSI breakpoints 59. Given that only high levels of resistance seemed to 
influence prescribing practices, this relatively low level of resistance under the new 
breakpoints should influence physicians to prescribe narrow spectrum antibiotics to treat 
S. pneumoniae. In previous studies, however, clinicians typically used antibiograms to 
prescribe broader spectrum empiric therapy and continued broad spectrum antibiotic 
therapy even when the bacteria were identified as susceptible to narrower spectrum 
antibiotics 72. This limited use of a potentially powerful tool contributes to the public 
health problem of antibiotic resistant bacteria. 
 CLSI determined breakpoints by reviewing the MICs, the pharmacokinetic and 
pharmacodynamic information for each antimicrobial/pathogen combination, and the data 
from clinical trials or well documented case series 73. The site from which the isolate 
originates (e.g. blood, respiratory secretions, CNS) is not always taken into account when 
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developing the breakpoints. Therefore the breakpoints do not always accurately reflect 
the potency of the antimicrobial in inhibiting the growth of the infecting pathogen at 
those specific sites of infection.  
 CLSI breakpoints that define the interpretative categories in antibiograms must 
align with clinical outcomes as they influence the choice of empiric therapy. 
Antibiograms are known to overestimate drug resistance in the community and prompt 
broad spectrum prescribing. Urinary tract infections, predominantly caused by 
Escherichia coli, are example of how breakpoints determined in vitro may contribute to 
broad spectrum antibiotic prescribing 74. This “false” equating of drug resistance with 
clinical treatment failure promotes a culture of broad spectrum antimicrobial prescribing 
for pathogens that are otherwise susceptible to narrower spectrum drugs in clinical 
settings. Urinary tract infections, however, also offer an opportunity for intervention 
whereby aligning in vitro susceptibility results with clinical outcomes could encourage 
narrower spectrum antibiotic use. 
 This study had several limitations. First, there is no information on the patients 
from whom these isolates were obtained and reported in the antibiograms. Variability in 
reported susceptibility patterns across hospitals may be due in part to the differences in 
the underlying patient populations 57. Antibiograms may overestimate community-level 
resistance because isolates are obtained from patients with specific indications for 
invasive testing and from patients with chronic medical conditions and consequently 
greater antibiotic exposure. Better measures of community-level resistance and better 
diagnostic tests to identify the cause of CAP in the emergency department or hospital 
settings are needed. 
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 Second, we assumed that the proportion of resistant or non-susceptible 
pneumococcal isolates reported by each hospital was the only measure that was 
disseminated to physicians and, consequently, influencing their prescribing practices. The 
outlier hospital in our study reported 46% of pneumococcal isolates to be nonsusceptible 
to penicillin, however this hospital had the highest proportion of aminopenicillin 
prescribing, 69%, when compared to the other hospitals. Therefore there are other 
determinants that affect antimicrobial prescribing which include hospital policies to direct 
prescribing (e.g. formulary restriction or prior authorization required), the preference of 
antibiotic in each subspecialty, the dynamic and expertise of the team of health 
professionals providing care 75.  
 Third, the use of ICD-9 codes to identify patients with CAP may result in 
misclassification of the disease. However, the ICD-9 codes used in this study are similar 
to previous studies that have shown a relatively high sensitivity and specificity for 
identifying CAP compared with medical record review 30, 31. Additional criteria that 
likely increased the specificity of these algorithms included restriction of the cohort to 
those receiving antibiotics conventionally used to treat CAP in children on the first day of 
hospitalization and exclusion of children with comorbid conditions. Children who 
received something other than conventional antibiotics made up less than 7% (n=369) of 
the original cohort.  While this approach may have lead to the exclusion of some 
previously healthy children with CAP, such as those with delayed recognition of CAP, 
these exclusions likely have a negligible influence on the overall estimates produced from 
this analysis. Fourth, this study was limited to freestanding children’s hospitals. The 
results, therefore, may not be generalizable to other healthcare settings.  
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 Lastly, limitations exist in the use of multi-level analysis. The fixed variables 
available for this analysis may not have accounted for all the different factors that drive a 
physician’s prescribing practice (i.e. the patient’s medical history). However, these 
unmeasured variables are by default incorporated into the random intercept in the model 
and could also explain some of the variability that was seen in the model 62.    
 In conclusion, high levels of resistance reported in an antibiogram were associated 
with broad spectrum empiric antibiotic therapy. This finding supports a strategy of better 
aligning antibiotic susceptibility reports and clinical outcomes to reduce broad spectrum 
antibiotic prescribing. Future studies using data after the CLSI breakpoints changed in 
2008 need to be conducted to confirm these findings. 
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TABLES 
 
 
 
Table 8: Variability in proportion of penicillin-nonsusceptibility in Streptococcus 
pneumoniae across all hospitalsa  
 
Main Exposure  Hospital 
Reported 
Data (No.) 
Media
n (%) 
Interquartil
e Range (%) 
Range 
(%) 
Penicillin-nonsusceptible S. 
pneumoniae  
    
All isolates 33 52 46-60 9-70 
Blood isolates 17 48 37-54 14-69 
Respiratory isolates 14 56 48-65 4-72 
Penicillin-resistant S. pneumoniae     
All isolates  20 25 18-30 0-60 
aAll numbers in table are the median percentages of the hospitals 
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Table 9: Characteristics of children hospitalized with community-acquired pneumonia 
stratified by empiric therapy 
 
Characteristics All 
Patients 
(N=5033) 
Narrow 
Spectrum 
Antibiotic  
(N=349) 
Broad 
Spectrum 
Antibiotic 
(N=4684) 
P-Valuea 
Median age (years) (IQR)  3 (2-7) 2 (1-4) 4 (1-7) <0.0001 
Male sex 2734 (54) 196 (56) 2538 (54) 0.5 
Asthma status     
Prior asthma hospitalization 644 (13) 61 (18) 583 (12) 0.01 
Chronic asthma medicationb 1040 (21) 92 (26) 948 (20) 0.0064 
Data are presented as number (percent) or median (interquartile range). 
Abbreviation: IQR, interquartile range. 
aCompared between Narrow Spectrum and Broad Spectrum Antibiotic 
bPatients were considered to be on chronic asthma therapy if they received an inhaled 
steroid or a leukotriene-receptor antagonist on admission. 
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Table 10: Random-intercept multilevel model predicting the probability of being 
prescribed aminopenicillinc 
 
Exposure Unadjusted 
Odds Ratio (95% CI) 
Adjusted 
Odds Ratioa (95% CI) 
Penicillin-nonsusceptible S. 
pneumoniae  
  
All isolates 0.89 (0.67, 1.17) 0.89 (0.60, 1.18) 
Blood isolates 1.01 (0.70, 1.48) 1.03 (0.61, 1.44) 
Respiratory isolates  0.91 (0.64, 1.31) 0.90 (0.50, 1.30) 
Penicillin-resistant S. pneumoniae    
All isolatesb 0.71 (0.61, 0.83) 0.72 (0.56, 0.88) 
Abbreviations: CI, confidence interval 
aAdjusted for age, prior hospitalization for asthma, and chronic asthma medication 
bThe outlier hospital did not report overall resistance and therefore is not included in this 
model 
cOdds ratios are given for every 10% change in penicillin-nonsusceptible or resistant 
pneumococcal isolate 
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Table 11: Median odds ratio for unadjusted and adjusted models 
 
Exposure Unadjusted Median 
Odds Ratio (95% 
CI) 
Adjusted Median 
Odds Ratioa (95% CI) 
Penicillin-nonsusceptible S. 
pneumoniae  
  
All isolates 2.67 (1.41, 5.04) 2.69 (1.41, 5.13) 
Blood isolates 2.98 (1.03, 8.65) 3.04 (1.01, 9.10) 
Respiratory isolates  2.98 (0.99, 8.99) 3.05 (0.97, 9.58) 
Penicillin-Resistant S. pneumoniae   
All isolatesb 1.71 (1.23, 2.38) 1.67 (1.23, 2.26) 
Abbreviations: CI, confidence interval 
aAdjusted for age, prior hospitalization for asthma, and chronic asthma medication 
bThe outlier hospital did not report overall resistance and therefore is not included in this 
model 
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Figure 1. Common antibiotic treatment prescribed per hospital 
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*Please note that PHIS Hospital number was randomly generated and is not correlated to the hospital numbers in the actual database. 
Also, hospital numbers 11, 12, and 28 were not included in this graph as discussed in the methods section.
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Chapter 4: Conclusions and recommendations 
 
 This thesis addressed two significant gaps in the existing literature on childhood 
pneumonia: 1. limited evidence exists to support the international recommendations for 
empiric therapy prescribed to children diagnosed with community-acquired pneumonia 
and 2. limited evidence exists on the true influence of antibiograms (hospital-reported 
susceptibility patterns) on antibiotic prescribing. These gaps were addressed using 
information submitted to a national database of freestanding, tertiary care children’s 
hospitals.   
 Evidence from the comparative effectiveness study conducted for this thesis 
demonstrates that patients who received beta-lactam and macrolide combination therapy 
on average had a shorter LOS compared to patients who received beta-lactam 
monotherapy. Children who were ≥ 6 years had a shorter LOS compared with children 1-
5 years old. There were no significant differences in LOS among the individual therapies. 
In addition, beta-lactam and macrolide combination therapy resulted in reduced hospital 
readmission within 14 days of index discharge, but the association was not statistically 
significant.  
  Antibiograms are associated with broad spectrum (i.e. non-penicillin) prescribing 
but only when high-levels (i.e. resistant) but not modest-levels (i.e. intermediate 
susceptibility) of penicillin-resistant Streptococcus pneumoniae were reported. This study 
also demonstrated that substantial variability exists in empiric antibiotic prescribing for 
CAP among children’s hospitals in the U.S. Variability in prescribing is a well-known 
driver of antibiotic resistance in the community. 
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 Recommendations from these studies are: 1. a randomized control trial is needed 
to address the benefit of combination therapy among older children; 2. strategies are 
needed to optimally align antibiotic susceptibility patterns and clinical outcomes as these 
can lead to meaningful decreases in broad spectrum antibiotic prescribing; and 3. further 
studies are needed to understand the reasons behind the variability that exists in empiric 
prescribing practices for childhood pneumonia. 
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Appendix A: Detailed study criteria 
 
 
 
 
A1.  VALIDATION OF ICD-9CM DISCHARRGE DIAGNOSIS CODES FOR CAP 
 
 Errors in coding for hospital discharge records can occur at various points during 
the process: diagnosing by the physician, medical record keeping, filing the discharge 
abstract form by the treating physician and the interpretation by the coding clerk 48.Many 
studies have been conducted evaluating the accuracy of using ICD-9 CM codes in 
identifying patients with pneumonia (TABLE 12). A study conducted in the Netherlands 
by van de Garde et al. found that when ICD-9 CM codes were used as the principal 
diagnosis of patients with pneumonia (ICD-9 CM codes: 481, 482.x, 483.x, 485, and 486) 
excluding patients who had cystic fibrosis, immunosuppressive conditions, or cancer, 
there was a sensitivity of 72.4% when the diagnosis was confirmed by microbiological 
analysis of the causative agent (specificity was not reported in this study) 48. In a similar 
study conducted in an adult population who were admitted to the emergency department 
at a hospital in Utah, three different algorithms were created using combinations of ICD-
9 CM codes for pneumonia and/or pneumonia-like symptoms 51. When only including the 
most common pneumonia ICD-9 CM codes (Algorithm 1: 480-483 and 485-487.0) for 
in-patients only, the investigators found a sensitivity of 54.8% and a specificity of 99.1%.  
The next algorithm included a wider spectrum of ICD-9 CM codes to include more 
possible cases of pneumonia cases and found a sensitivity and specificity for in patients 
of 68.3% and 99.0% respectively 51.  
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 The range of ICD-9 CM codes used in this study are not as extensive as those in 
the second algorithm but are more extensive than the ones stated in the first algorithm, 
therefore the sensitivity and specificity of this combination of ICD-9 CM codes would 
most likely be somewhere between 54-68% and 99-99.1% respectively. However these 
studies did not specifically try to differentiate between community-acquired pneumonia 
(CAP) and hospital-acquired pneumonia (HAP). ICD-9 CM codes for pneumonia do not 
differentiate as to how the pneumonia was acquired.  
 Whittle et al. and Guevara et al. conducted studies to determine the accuracy of 
using ICD-9 CM codes in combination with other exclusion criteria in identifying CAP. 
Patients were included in the Whittle et al. study if they had symptoms compatible with 
pneumonia with 24 hours of hospital admission and had a chest radiograph performed 
within 48 hours of admission that confirmed the presence of pneumonia. The exclusion 
criteria included pneumonia that was diagnosed with 10 days of discharge or if symptoms 
compatible with pneumonia were diagnosed after the initial 24 hour period of 
hospitalization or they had a diagnosis code indicating a major trauma or elective surgery 
as these cases are indicative of HAP. In addition patients were excluded if they had a 
diagnosis code of HIV/AIDS or organ transplantation as the pneumonia in these patients 
is clinically distinct from CAP 49. The sensitivity and specificity of the diagnostic criteria 
in patients with a principal diagnosis code of pneumonia only was 84% and 86% 
respectively or a sensitivity and specificity of 89% and 80% respectively if patients had a 
principal diagnosis code related to pneumonia when cases were confirmed with medical 
chart reviews 49.  
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 Guevara et al. conducted a study in not only detecting CAP from ICD-9 CM 
codes but specifically CAP pneumococcal pneumonia caused by Streptococcus 
pneumoniae, the most prevalent cause of pneumonia 50. This study included adult patients 
who had no other hospitalization within 30 days of the pneumonia diagnosis and had a 
chest radiograph taken with 48 hours of admission which was consistent with a diagnosis 
of pneumonia. The causative agent of pneumonia was confirmed with microbiological 
findings as indicated in the medical chart review. In general the most sensitive ICD-9 CM 
code to detect pneumococcal pneumonia was 481.00. However sensitivity was increased 
when more commonly cited ICD-9 CM codes were used (i.e. 38.00, 38.20, 38.80, 482.30, 
486.00 and 518.81)50. 
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Table 12: Comparison of ICD-9 Algorithms in identifying patients with pneumonia 
 
Author (Year) Study 
Population 
Validation Test ICD-9 
Algorithm 
Sensitivity 
(%) 
Specificity (%) PPV 
(%) 
NPV 
(%) 
van de Garde et al. 
(2007)48 
293 adult 
patients 
discharged from  
7 Netherland 
hospitals  
Sputum 
samples and 
blood samples 
for specific 
etiology 
481-483, 485-
486 
 
72.4 NR NR NR 
Whittle et al.  
(1997)49 
212 adult 
patients 
discharged from  
Presbyterian 
University 
Hospital (US) 
Chart review of 
symptoms 
compatible with 
pneumonia 
present within 
24 hours of 
admission and 
official reading 
of chest 
radiography 
NR 89 80 89 NR 
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Table 12 (continued): Comparison of ICD-9 Algorithms in identifying patients with pneumonia 
 
Author (Year) Study 
Population 
Validation Test ICD-9 
Algorithm 
Sensitivity 
(%) 
Specificity (%) PPV 
(%) 
NPV 
(%) 
Guevara et al. 
(1999)50 
4,385 adult 
patients in 15 
acute-care 
hospitals in 
Ohio (US) 
Streptococcus 
pneumonia 
isolated from 
blood or pleural 
isolates  
Group 1: 
38.20 
 
Group 2: 
38.20, 481.00 
 
Group 3: 
38.20, 481.00, 
38.00 
 
Group 4: 
38.20, 481.00, 
38.00, 482.30 
 
Group 5: 
38.20, 481.00, 
38.00, 482.30, 
518.81 
 
Group 6: 
38.20, 481.00, 
38.00, 482.30, 
518.81, 
486.00 
8.38 
 
55.61 
 
 
60.96 
 
 
72.19 
 
 
 
72.19 
 
 
 
85.03 
99.95 
 
97.41 
 
 
96.97 
 
 
96.05 
 
 
 
96.03 
 
 
 
44.53 
95.92 
 
75.91 
 
 
74.67 
 
 
72.84 
 
 
 
72.71 
 
 
 
18.36 
88.15 
 
93.73 
 
 
94.42 
 
 
95.93 
 
 
 
95.92 
 
 
 
95.30 
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Table 12 (continued): Comparison of ICD-9 Algorithms in identifying patients with pneumonia 
 
Author (Year) Study 
Population 
Validation Test ICD-9 
Algorithm 
Sensitivity 
(%) 
Specificity (%) PPV 
(%) 
NPV 
(%) 
Aronsky et al. 
(2005)51 
199 patients 
admitted in 
LDS Hospital in 
Utah (US) 
Chart review Algorithm 1: 
480-483 
 
Algorithm 2: 
480-487.0, 
507 
 
Algorithm 3: 
480-483, 485-
487.0, 507 
54.8 
 
 
68.3 
 
 
69.8 
 
 
 
99.1 
 
 
99.0 
 
 
98.9 
84.5  
 
 
85.5 
 
 
84.8 
96.1 
 
 
97.2 
 
 
97.3 
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Table 13 and table 14 describe the ICD-9CM codes that were used to define the cohort 
for this dissertation. 
 
 
 
Table  13: Pneumonia-related ICD-9CM* discharge diagnosis coding used for this 
dissertation to identify Community Acquired Pneumonia patients  
 
Diagnosis ICD-9CM Code 
Pneumonia 481-483.8, 485-486 
Pneumonia-related Symptoms:  
      Fever 780.6 
      Respiratory abnormality, unspecified 786.00 
      Shortness of breath 786.05 
      Tachypnea 786.06 
      Wheezing 786.07 
      Cough 786.2 
      Hemoptysis 786.3 
      Abnormal Sputum 786.4 
      Chest Pain 786.50 
      Precordial Pain 786.51 
      Painful Respiration 786.52 
Empyema or pleurisy 510.0, 510.9, 511.0, 511.1, 511.9 
*International Classification of Diseases, 9th Revision, Clinical Modification  
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Table 14: Summary of Exclusion Criteria in this study 
 
Diagnosis ICD-9CM Code* 
Human Immunodeficiency Virus 042 
Malignancy 140.x-165.x, 170.x-172.x, 174-175.9, 19.x-
208.x 
Cystic Fibrosis 277.00, 277.01, 277.02, 277.03, 277.09 
Immune Mechanism Disorder 279.00- 279.13,279.19, 279.2, 279.3, 279.4, 
279.8, 279.9, 334.8 
Sickle Cell 282.60-282.64, 282.68, 282.69 
Disease of White Blood Cells 288.00-288.59, 288.8, 288.9 
Encounter for Radiation, Chemotherapy V58.0, V58.11, V58.12 
Transplant V42.0-V42.89 
Other Lung Conditions 507.0, 507.1, 507.8, 517.1, 517.2, 517.3, 
517.8 
Congenital Heart Defects 745.0, 745.10, 745.11, 745.12, 745.19, 745.2, 
745.3, 745.4, 745.5, 745.60, 745.61, 745.69, 
745.7, 745.8, 745.9, 746.0, 746.01, 746.02, 
746.09, 746.1, 746.2, 746.3, 746.4, 746.5, 
746.6, 746.7, 746.81, 746.82, 746.83, 746.84, 
746.85, 746.86, 746.87, 746.89, 746.9, 747.0, 
747.11, 747.20, 747.21, 747.22, 747.29, 
747.3, 747.40, 747.41, 747.42, 747.49, 747.83
Prematurity 765.0, 765.1, 765.20-765.25 
**International Classification of Diseases, 9th Revision, Clinical Modification 
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A2. OUTCOME MEASURES FOR PEDIATRIC PNEUMONIA 
  Since mortality is a rare consequence of pediatric CAP in the U.S., other 
indicators have been used in previous studies to quantify a more positive or more 
negative resolution of disease. These indicators include length of stay in hospital, total 
hospital charges and rates of hospital readmission for the same episode of pneumonia. 
 Length of hospital stay has been used previously in research that uses 
administrative claims data as a way to evaluate the quality of medical care within 
hospitals 53, 76. This measure may be drastically different for two individuals who receive 
the same primary diagnosis due to non-clinical factors such as age of the patient, type of 
insurance, race of the patient, and the location and teaching-status of the hospital 53. It has 
been argued that for pediatric care, freestanding children’s hospitals are most important 
when specialty care is needed (i.e. uncommon surgeries, oncology, and rare conditions) 
and are not any better equipped medically than other hospitals in regards to common 
conditions such as asthma or pneumonia. It has been assumed that patients seen at 
children’s hospitals have generally longer length of stays and greater hospital charges 
when compared to patients seen at other hospitals for the same diagnosis. In a study 
conducted by Merenstein et al., no statistical difference was found in the median length 
of stay when comparing freestanding children’s hospitals to other hospitals but 
freestanding children’s hospitals did have significantly higher hospital charges compared 
to other hospitals when adjusting for the non-clinical patient characteristics mentioned 
above 53. This illustrates the importance in adjusting for these factors when comparing 
patients from different hospitals even if the patients have similar conditions.  
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Hospital readmission rates are dependent on multiple factors such as age, insurance status 
and longer lengths of stay during the initial admission 46, 77. In one study twenty-four 
percent of adults who were diagnosed with CAP were readmitted to the hospital within 
thirty days of their index discharge 77. It is unclear whether a similar rate of readmission 
exists in children.  
 A study where adult patients (65 years and older) hospitalized with CAP were 
given antibiotics according to the Infectious Disease Society of America (IDSA) 2009 
Guidelines for adult pneumonia, found that these patients had a shorter length of stay, a 
decrease in CAP-related mortality and a shorter amount time to reaching clinical stability 
compared to a similar population of patients who did not receive antibiotics according to 
IDSA guidelines 78. Similar results would be favorable in the pediatric population; 
however no such national guidelines currently exist for children with CAP. This lack of 
national guidelines in clinical management of pediatric pneumonia leads to large 
variability within the field.  
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A3. COMPARISON OF SEVERITY INDEX MEASURES 
 
 Severity index measures are useful for two reasons: 1. they aid in the 
identification of subpopulations who are comparably more ill and 2. They allow for 
epidemiologist to adjust for severity of illness more accurately. For patients diagnosed 
with pneumonia, the Pneumonia Severity Index (PSI) is the gold standard in identifying 
patients with different risk factors who have a higher 30-day mortality rate. Patients are 
assigned to one of five risk classes based on their overall PSI score. Points are assigned 
for the presence of different symptoms, such as older age, coexisting illness, higher 
temperature, high respiratory rate, etc. The higher the overall score the higher the risk of 
30-day mortality. Although the PSI was created in 1997 and has since been extensively 
studied, it has only been validated in adults. It is not possible for PSI to be validated in 
children since many of the measures used to obtain the overall score do not directly apply 
to children.  The Charlson Index which has also been validated in adults is only useful in 
predicting mortality based on comorbid conditions but less than 1% of children diagnosed 
with pneumonia die from the disease. Therefore the usefulness of this measure in 
predicting disease severity for children with pneumonia is limited. The Pediatric Risk of 
Mortality (PRISM) Score is the most well known severity score for children. It is similar 
to PSI in its use of different risk factors found on physical finding to calculate a risk score 
to predict ICU mortality. Similar to the Charlson Index, PRISM is validated in predicting 
mortality risk for children admitted to the ICU. Generally only a small proportion of 
children are admitted to the ICU with a diagnosis with pneumonia and the majority of 
these children have an underlying comorbid condition which makes their treatment 
drastically different than children who are otherwise healthy except for their diagnosis of 
pneumonia. Therefore there is a great need for a pneumonia severity index specifically 
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created and validated in children. This pneumonia index for children should be informed 
by the other measures that have been developed and well validated. 
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Table 15: Severity index measures 
 
Index Measure Population in which 
Validated 
Variables Predicted Outcome 
Pediatric Risk of 
Mortality (PRISM) 
Score79 
(Pollack et al. 1988)  
Children  Systolic Blood Pressure 
Diastolic Blood Pressure 
Heart Rate 
Respiratory Rate 
PaO2/FIO2 
PaCO2 
Glasgow Coma Score 
Pupillary Reactions 
PT/PTT 
Total Bilirubin 
Potassium 
Calcium 
Glucose 
Bicarbonate 
 
Predicts ICU mortality risk in 
children. 
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Table 15 (continued): Severity index measures 
 
Index Measure Population in which 
Validated 
Variables Predicted Outcome 
Charlson Index80 
(Charlson et al., 1987) 
Adults Myocardial Infarction 
Congestive Heart Failure 
Peripheral  Vascular Disease 
Cerebrovascular Disease 
Dementia 
Chronic Pulmonary Disease 
Connective Tissue Disease 
Ulcer Disease 
Diabetes  
Hemiplegia 
Moderate or Severe Renal Disease 
Diabetes with End Organ Damage 
Any Tumor 
Leukemia 
Lymphoma 
Moderate or Severe Liver Disease 
Metastatic Solid Tumor 
AIDS 
Predicts mortality based on comorbid 
conditions. 
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Table 15 (continued): Severity index measures 
 
Index Measure Population in which 
Validated 
Variables Predicted Outcome 
Pneumonia Severity 
Index (PSI)81 
(Fine et al, 1997) 
Adults Age  
Neoplastic Disease 
Congestive Heart Failure 
Cerebrovascular Disease 
Renal Disease 
Liver Disease 
Altered Mental Status 
Pulse  
Respiratory Rate  
Systolic Blood Pressure 
Temperature 
Nursing Home Resident 
Arterial pH 
BUN 
Sodium 
Glucose 
Hematocrit 
Partial Pressure of Arterial Oxygen 
 Pleural Effusion 
Predicts severity risk and mortality 
risk for patients diagnosed with 
community-acquired pneumonia. 
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Appendix B: Additional analysis for the comparative effectiveness study  
 
 
 
 
B1. ACRONYMS 
 
LOS: length of stay 
 
Prior Hospitalization: Any hospitalization within the prior 24 months (to their 
hospitalization with CAP) where there was a diagnosis of asthma.  
 
Chronic Asthma Med: Treatment with inhaled corticosteroids (e.g., fluticasone) or 
leukotriene receptor antagonists on the first day of hospitalization for CAP  
 
Systemic Steroid: Systemic (either oral or intravenous) corticosteroids (e.g. 
dexamethasone, hydrocortisone, methylprednisolone, prednisolone, and prednisone 
received on the first day of hospitalization for CAP.  
 
Acute Wheeze: Receipt of beta agonist therapy on the first day of hospitalization for CAP 
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B2. DESCRIPTIVE ANALYSIS  
 
 
 
Figure 2: Change of empiric therapy by year 
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Linear trend test showed no statistically significant differences in year prescribed for any of the therapies prescribed. 
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 Figure 3: Distribution of LOS 
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Note: Kolmogorov-Smirnov test p-value <0.010 so statistically different than a normal Gaussian curve. Right skewed and over 
dispersed around 1-2 days. 
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Figure 3: Exclusion criteria flow chart 
 
37,461 children who had a diagnosis of CAP and received an antibiotic on the first day 
23, 755 children who received a β-lactam and/or macrolide on the first day 
23,735 children who did not have a pleural fluid procedure done 
23, 439 children who did not receive mechanical respiratory support 
23,084 children who did not receive vasoactive infusions (epinephrine, norepinephrine, 
dopamine, and dobutamine) 
20,747 children were not admitted to the ICU 
20,743 children who did not receive blood product administration (packed or washed red 
blood cells, fresh frozen plasma, and coagulation factors) 
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B3. UNIVARIATE ASSOCIATIONS 
 
 
 
Table 16: Univariate associations of hospital readmission within 14 days among patients who received beta-lactam-macrolide 
combination compared to beta-lactam monotherapy 
 
  
Combo Therapy  
(Reference: 
Monotherapy) 
OR (95% CI) 
 
Confounder 
OR (95% CI) 
 
% Change in Combo 
Therapy Effect Estimate 
*Unadj. for other 
variables 
Combo Therapy (Reference: Monotherapy) 0.774 (0.485, 1.234) N/A  
Length of Stay 0.793 (0.497, 1.266) 1.036 (1.022, 1.051) 2% 
Age-in-years 0.678 (0.421, 1.092) 1.060 (1.018, 1.103) 12% 
Principal Payer (Reference: Government)    
Non-Government 0.772 (0.484, 1.231) 1.114 (0.727, 1.709) 0.3% 
Other  0.838 (0.511, 1.373)  
No Charge  2.338 (0.320, 17.104)  
Asthma (Reference: No)    
Prior Hospitalization 0.771 (0.484, 1.230) 1.451 (0.894, 2.356) 0.4% 
Chronic Asthma Med 0.763 (0.478, 1.218) 1.501 (0.978, 2.305) 1% 
Systemic Steroid 0.785 (0.492, 1.253) 0.711 (0.468, 1.081) 1% 
Acute Wheeze 0.795 (0.498, 1.269) 0.684 (0.472, 0.993) 3% 
Other Variables (Reference: No)    
Arterial Blood Gases 0.763 (0.472, 1.231) 1.601 (0.875, 2.928) 1% 
Intensive Imaging 0.773 (0.485, 1.232) 1.343 (0.330, 5.460) 0.1% 
Combo Therapy (Reference: Monotherapy) 0.738 (0.451, 1.205) Fully Adjusted 5% 
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Table 16 (continued): Univariate associations of hospital readmission within 14 days among patients who received beta-lactam-
macrolide combination compared to beta-lactam monotherapy 
 
  
Combo Therapy  
(Reference: 
Monotherapy) 
OR (95% CI) 
 
Confounder 
OR (95% CI) 
 
% Change in Combo 
Therapy Effect Estimate 
*Unadj. for other 
variables 
Interaction Terms (Tested in model adjusted for 
age only)* 
   
Combo and Anydx_prior_24mo 0.679 (0.402, 1.147) 1.00 (0.30, 3.38) 0.1% 
Combo and Chronic_asthma_med 0.658 (0.39, 1.12) 1.15 (0.423, 3.13)  3% 
Combo and Systemic_steroid_00 0.721 (0.413, 1.26) 0.86 (0.30, 2.47) 6% 
Combo and Acute_wheeze_1 0.637 (0.321, 1.265) 1.21 (0.47, 3.08) 6% 
*Difference tested from main effect estimate in model adjusted for age only 
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Table 17: Univariate associations of hospital readmission within 14 days among patients who received beta-lactam monotherapy 
 
 2nd Gen. 
Cephalosporin 
(Ref: Ampcn) 
OR (95% CI) 
3rd Gen. 
Cephalosporin 
(Ref: Ampcn) 
OR (95% CI) 
% ∆ 2nd Gen 
Ceph 
% ∆ 3rd Gen 
Ceph 
Confounder  
OR (95% CI) or P-
Value for Int. Terms 
2nd Gen Ceph (Ref: Ampcn) 1.274 (0.728, 
2.231) 
- 0% N/A N/A 
3rd Gen Ceph (Ref: Ampcn) - 1.071 (0.704, 
1.629) 
N/A 0% N/A 
Length of Stay  1.279 (0.730, 
2.241) 
1.043 (0.685, 
1.587) 
0.4% 3% 1.037 (1.022, 1.052) 
Age-in-years 1.415 (0.803, 
2.493) 
1.147 (0.751, 
1.749) 
11% 7% 1.056 (1.015, 1.098) 
Principal Payer (Ref: 
Government) 
     
Non-Government 1.268 (0.724, 
2.222) 
1.073 (0.705, 
1.634) 
0.5% 0.2% 1.110 (0.723, 1.702) 
Other - -   0.841 (0.513, 1.380) 
No Charge - -   2.357 (0.321, 17.292) 
Asthma (Ref: No)      
Prior Hospitalization 1.285 (0.734, 
2.250) 
1.083 (0.712, 
1.647) 
0.9% 1% 1.454 (0.895, 2.361) 
Chronic_Asthma_Med 1.301 (0.743, 
2.280) 
1.088 (0.715, 
1.655) 
0.9% 1.6%  
Systemic Steroid 1.266 (0.723, 
2.217) 
1.033 (0.678, 
1.574) 
0.6% 4% 0.703 (0.462, 1.071) 
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Table 17 (continued): Univariate associations of hospital readmission within 14 days among patients who received beta-lactam 
monotherapy 
 
 2nd Gen. 
Cephalosporin 
(Ref: Ampcn) 
OR (95% CI) 
3rd Gen. 
Cephalosporin 
(Ref: Ampcn) 
OR (95% CI) 
% ∆ 2nd Gen 
Ceph 
% ∆ 3rd Gen 
Ceph 
Confounder  
OR (95% CI) or P-
Value for Int. Terms 
Acute Wheeze 1.262 (0.721, 
2.210) 
1.032 (0.678, 
1.572) 
0.9% 4% 0.676 (0.465, 0.981) 
Other Variables (Ref: No)      
Arterial Blood Gases 1.513 (0.847, 
2.703) 
1.227 (0.785, 
1.918) 
19% 15% 1.577 (0.863, 2.883) 
Intensive Imaging 1.274 (0.727, 
2.230) 
1.071 (0.704, 
1.628) 
0% 0% 1.323 (0.325, 5.380) 
Partially Adjusted Model 1.675 (0.931, 
3.013) 
1.314 (0.837, 
2.063) 
31% 23% Adjusted for age and 
ABG 
Fully Adjusted Model* 1.627 (0.904, 
2.929) 
1.227 (0.779, 
1.933) 
3% 7% Fully adjusted model 
Interaction Terms (Tested in 
model adjusted for age and 
ABG)** 
     
Monoabx and 
Anydx_prior_24mo 
1.67 (0.88, 3.17) 1.25 (0.76, 2.05) 0.3% 5% Abx2*Prior:0.97 
Abx3*Prior:0.62 
Monoabx and 
Chronic_Asthma_Med 
1.58 (0.84, 2.97) 1.12 ( 0.69, 
1.81) 
6% 15% Abx2*chronic: 1.35 
(0.45,4.09) 
Abx3*chronic: 1.95 
(1.10, 3.45) 
Monoabx and 
Systemic_steroid_00 
1.70 (0.83, 3.48) 1.36 (0.79, 2.33) 1% 4% Abx2*Sys:0.90 
Abx3*Sys:0.64 
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Table 17 (continued): Univariate associations of hospital readmission within 14 days among patients who received beta-lactam 
monotherapy 
 
 2nd Gen. 
Cephalosporin 
(Ref: Ampcn) 
OR (95% CI) 
3rd Gen. 
Cephalosporin 
(Ref: Ampcn) 
OR (95% CI) 
% ∆ 2nd Gen 
Ceph 
% ∆ 3rd Gen 
Ceph 
Confounder  
OR (95% CI) or P-
Value for Int. Terms 
Monoabx and Acute_wheeze_1 1.37 (0.57, 3.29) 1.39 (0.75, 2.59) 18% (only 
8% from 
unadj. model) 
 
6% Abx2*Wheeze: 0.56 
Abx3*Wheeze: 0.65 
*Difference tested from main effect estimates in partially adjusted model  
 **Difference tested from main effect estimates in model adjusted for age and ABG only 
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Table 18: Univariate associations of LOS among patients who received Beta-lactam-macrolide combination compared to Beta-lactam 
monotherapy 
 
  
Combo Therapy  
(Reference: Monotherapy) 
RR (95% CI) 
 
Confounder 
RR (95% CI) 
 
% Change in Combo 
Therapy Effect Estimate 
*Unadj. for other 
variables 
Combo Therapy (Reference: Monotherapy) 0.9125 (0.8689, 0.9583) N/A 0% 
Age-in-years 0.8348 (0.7904, 0.8818) 1.046 (1.0367, 1.0552) 9% 
Principal Payer (Reference: Government)    
Non-Government 0.9165 (0.8727, 0.9625) 0.8780 (0.8200, 0.9402) 0% 
Other 0.9165 (0.8727, 0.9625) 0.8487 (0.7839, 0.9188)  
No Charge 0.9165 (0.8727, 0.9625) 0.7162 (0.6562, 0.7817)  
Asthma (Reference: No)    
Prior Hospitalization 0.9109 (0.8680, 0.9559) 1.2373 (1.1692, 1.3094) 0% 
Chronic Asthma Medication 0.9105 (0.8674, 0.9558) 1.0816 (1.0071, 1.1617)  
Systemic Steroid 0.9239 (0.8811, 0.9687) 0.8052 (0.7596, 0.8537) 1% 
Acute Wheeze 0.9191 (0.8760, 0.9644) 0.9129 (0.8691, 0.9589) 1% 
Other Variables (Reference: No)    
Arterial Blood Gases 0.9024 (0.8562, 0.9511) 1.3391 (1.2363, 1.4505) 1% 
Intensive Imaging 0.9009 (0.8542, 0.9502) 1.5832 (1.3692, 1.8306) 1% 
Combo Therapy (Reference: Monotherapy) 0.8446 (0.8008, 0.8907) Fully Adjusted Model 8% 
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Table 18 (continued): Univariate associations of LOS among patients who received Beta-lactam-macrolide combination compared to 
Beta-lactam monotherapy 
 
  
Combo Therapy  
(Reference: Monotherapy) 
RR (95% CI) 
 
Confounder 
RR (95% CI) 
 
% Change in Combo 
Therapy Effect Estimate 
*Unadj. for other 
variables 
Interaction Terms (Tested in fully adjusted 
model) 
   
Combo and Anydx_prior_24mo 0.8456 (0.7917, 0.9032) 1.00 (0.91, 1.10) 7% 
Combo and Chronic Asthma Medication 0.8419 (0.7883, 0.8991) 0.99 (0.89, 1.10)  8% 
Combo and Systemic_steroid_00 0.8595 (0.8153, 0.9601) 1.12 (1.05, 1.20) 6% 
Combo and Acute_wheeze_1 0.8413 (0.7974, 0.8878) 1.05 (0.95, 1.15) 8% 
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Table 19: Univariate associations of LOS among patients who received beta-lactam monotherapy 
 
 2nd Gen. 
Cephalosporin 
(Ref: Ampcn) 
RR (95% CI) 
3rd Gen. 
Cephalosporin 
(Ref: Ampcn) 
RR (95% CI) 
 
% ∆ 2nd Gen 
Ceph 
 
% ∆ 3rd 
Gen 
Ceph 
Confounder  
RR (95% CI) or P-
value for Int. Terms 
unless stat. sig. 
2nd Gen Ceph (Ref: Ampcn) 1.06 (0.96, 1.17) - 0% N/A N/A 
3rd Gen Ceph (Ref: Ampcn) - 1.16 (1.05, 1.28) N/A 0% N/A 
Age-in-years 1.06 (0.97, 1.16) 1.11 (1.02, 1.21) 0% 4% 1.05 (1.04, 1.06) 
Principal Payer (Ref: 
Government) 
     
Non-Government 1.04 (0.95, 1.15) 1.14 (1.03, 1.26) 2% 2% 0.90 (0.84, 0.97) 
Other - -   0.85 (0.78, 0.94) 
No Charge - -   0.73 (0.68, 0.79) 
Asthma (Ref: No)      
Prior Hospitalization 1.07 (0.97, 1.18) 1.17 (1.06, 1.30) 1% 1% 1.24 (1.16, 1.33) 
Chronic Asthma Med 1.07 (0.97, 0.97)  1.16 (1.05, 1.29) 1% 0% 1.09 (1.00, 1.19) 
Systemic Steroid 1.05 (0.95, 1.15) 1.12 (1.01, 1.24) 1% 3% 0.79 (0.74, 0.85) 
Acute Wheeze 1.06 (0.96, 1.17) 1.15 (1.04, 1.28) 0% 1% 0.91 (0.85, 0.96) 
Other Variables (Ref: No)      
Arterial Blood Gases 1.02 (0.92, 1.14) 1.11 (0.99, 1.24) 4% 3% 1.35 (1.23, 1.48) 
Intensive Imaging 1.02 (0.91, 1.13) 1.11 (0.99, 1.24) 4% 3% 1.61 (1.36, 1.91) 
Fully Adjusted Model 1.01 (0.91, 1.12) 1.03 (0.94, 1.14) 5% 11% Fully adjusted model 
Interaction Terms (Tested in 
fully adjusted model)* 
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Table 19 (continued) : Univariate associations of LOS among patients who received beta-lactam monotherapy 
 
 2nd Gen. 
Cephalosporin 
(Ref: Ampcn) 
RR (95% CI) 
3rd Gen. 
Cephalosporin 
(Ref: Ampcn) 
RR (95% CI) 
 
% ∆ 2nd Gen 
Ceph 
 
% ∆ 3rd 
Gen 
Ceph 
Confounder  
RR (95% CI) or P-
value for Int. Terms 
unless stat. sig. 
Monoabx and Anydx_prior_24mo 0.99 (0.88, 1.12) 1.08 (0.95, 1.22) 7% 7% Abx1*Prior:0.2446 
Abx2*Prior: 0.0988 
Monoabx and 
Chronic_asthma_med 
0.99 (0.88, 1.11) 1.08 (0.96, 1.21) 7% 7% Abx1*Chronic: 1.17 
(0.97, 1.42) 
Abx2*Chronic: 1.23 
(1.13, 1.34) 
Monoabx and 
Systemic_steroid_00 
1.01 (0.93, 1.11) 1.04 (0.95, 1.13) 5% 10% Abx1*Sys: 0.4735 
Abx2*Sys: 0.6976 
Monoabx and Acute_wheeze_1 1.00 (0.90, 1.12) 1.03 (0.93, 1.14) 6% 11% Abx1*Wh-RR: 1.24 
(1.03, 1.49) 
Abx2*Wh-RR: 1.15 
(1.03, 1.28) 
Mon0abx * Chronic and 
Monoabx*Acute 
0.98 (0.84, 1.13) 1.05 (0.92, 1.21)   Abx*Chronic (0.47 & 
0.0005) 
Abx* Wheeze (0.08 & 
0.11) 
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Table 20: Univariate associations of LOS among patients who received beta-lactam-macrolide combination 
 
 2nd Gen. 
Cephalosporin 
+Macrolide 
(Ref: 
Ampcn+Macrolide) 
RR (95% CI) 
3rd Gen. 
Cephalosporin+Macrolide 
(Ref: Ampcn+Macrolide) 
RR (95% CI) 
 
% ∆ 2nd 
Gen Ceph 
 
% ∆ 3rd 
Gen Ceph 
Confounder  
RR (95% CI) or P-
values for 
interaction terms 
2nd Gen Ceph + Macrolide 
(Ref: Ampcn+Macrolide) 
1.03 (0.93, 1.15) - 0% N/A N/A 
3rd Gen Ceph +Macrolide 
(Ref: Ampcn+Macrolide) 
- 0.88 (0.77, 1.01) N/A 0% N/A 
Age-in-years 1.01 (0.91, 1.12) 0.87  (0.76, 0.99) 2% 1% 1.03 (1.02, 1.04) 
Principal Payer (Ref: 
Government) 
     
Non-Government 1.03 (0.93, 1.15) 0.89 (0.77, 1.03) 0% 1% 0.81 (0.73, 0.91) 
Other     0.85 (0.78, 0.92) 
No Charge     0.79 (0.72, 0.87) 
Asthma (Ref: No)      
Prior Hospitalization 1.03 (0.93, 1.14) 0.87 (0.75, 0.99) 0% 1% 1.26 (1.19, 1.33) 
Chronic Asthma Med 1.03 (0.93, 1.15) 0.87 (0.76, 1.00) 0% 1% 1.07 (0.97, 1.17) 
Systemic Steroid 1.02 (0.92, 1.14) 0.90 (0.79, 1.03) 1% 2% 0.88 (0.82, 0.95) 
Acute Wheeze 1.03 (0.93, 1.15) 0.88 (0.77, 1.01) 0% 0% 0.96 (0.89, 1.04) 
Other Variables (Ref: No)      
Arterial Blood Gases 1.03 (0.91, 1.15) 0.90 (0.79,l 1.03) 0% 2% 1.29 (1.18, 1.41) 
Intensive Imaging 1.02 (0.91, 1.15) 0.90 (0.79, 1.03) 1% 2% 1.51 (1.23, 1.86) 
Fully Adjusted Model 1.01 (0.90, 1.13) 0.91 (0.79, 1.04) 2% 3% Fully Adjusted 
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Table 20 (continued): Univariate associations of LOS among patients who received beta-lactam-macrolide combination 
 
 2nd Gen. 
Cephalosporin 
+Macrolide 
(Ref: 
Ampcn+Macrolide) 
RR (95% CI) 
3rd Gen. 
Cephalosporin+Macrolide 
(Ref: Ampcn+Macrolide) 
RR (95% CI) 
 
% ∆ 2nd 
Gen Ceph 
 
% ∆ 3rd 
Gen Ceph 
Confounder  
RR (95% CI) or P-
values for 
interaction terms 
Interaction Terms (Tested in 
fully adjusted model) 
     
Comboabx and 
Anydx_prior_24mo 
1.01 (0.87, 1.16) 0.90 (0.76, 1.08) 2% 2% Abx1*Prior: 0.86 
Abx2*Prior: 0.88 
Comboabx and 
Chronic_asthma_med 
1.00 (0.88, 114) 0.89 (0.79, 1.00) 3% 0% Abx1*Chronic:0.35
Abx2*Chronic: 
0.42 
Comboabx and 
Systemic_steroid_00 
1.00 (0.88, 1.13) 0.91 (0.79, 1.04) 3% 3% Abx1*Sys:0.40 
Abx2*Sys:0.67 
Comboabx and 
Acute_wheeze_1 
1.01 (0.90, 1.13) 0.90 (0.79, 1.02) 2% 2% Abx1*Wheeze: 
0.56 
Abx2*Wheeze: 
0.34 
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B4. Model Diagnostics 
 
 
 
Figure 5. Hospital readmission model: 
 
No influential points or outliers in the readmission model after adjustment for age and 
ABG. 
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Figure 5 (continued). Hospital readmission model: 
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Figure 6. LOS Model 
 
 
 
Note: Age adequately fits the LOS fully adjusted model 
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Appendix C: Additional analysis for antibiogram study 
 
 
 
 
C1. ACRONYMS 
 
PNNS_ALL: Penicillin-Nonsusceptible S. pneumoniae (all isolates) 
 
PNNS_BLOOD: Penicillin-Nonsusceptible S. pneumoniae (isolates from blood only) 
 
PNNS_RESP: Penicillin-Nonsusceptible S. pneumoniae (isolates from respiratory 
secretions only) 
 
PNRES_ALL: Penicillin-Resistant S. pneumoniae (all isolates) 
 
Anydx_prior_24mo: Any hospitalization within the prior 24 months (to their 
hospitalization with CAP) where there was a diagnosis of asthma.  
 
Systemic_steroid_00: Systemic (either oral or intravenous) corticosteroids (eg. 
dexamethasone, hydrocortisone, methylprednisolone, prednisolone, and prednisone 
received on their first day of hospitalization for CAP. 
 
AIC: Akaike Information Criterion 
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C2. ANTIBIOGRAM SURVEY 
 
 
 
Figure 7: Antibiogram survey sent to participating hospitals  
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C3. TRANSFORMATION ANALYSIS OF MAIN EXPOSURE  
 
 
 
Table 21a: Transformations of PNNS_ALL Variable with Outlier 
 
Regressor Model 1 (SE) Model 2 (SE) Model 3 (SE) Model 4 (SE) 
Intercept -2.2272 (0.9688) -0.3209 (3.4437) -3.8292 
(3.7887) 
-3.0235 
(0.2014) 
PNNS_ALL (Continuous) -0.01561 (0.0182) - 0.05246 
(0.1567) 
- 
PNNS_ALL (Log Transformed) - -0.6916 (0.8802) - - 
PNNS_ALL (Quadratic) - - -0.00069 
(0.001576) 
- 
PNNS_ALL (Grand Mean Centered) - - - -0.01562 
(0.01862) 
*-2 Log Likelihood Test (df)* 2235.1 (1) 2235.2 (1) 2234.9 (2) 2235.1 (1) 
*Test Statistic (p-value)* 1.0 (>0.05) 0.9  (>0.05) 1.2  (>0.05) 1.0 (>0.05) 
***Variance**** 1.0610 (0.3329) 1.0634 (0.3235) 1.0647 
(0.3258) 
1.0610 
(0.3229) 
***AIC*** 2241.1 2241.2 2242.9 2241.1 
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Table 21b: Transformations of PNNS_ALL Variable without Outlier 
 
Regressor Model 1 (SE) Model 2 (SE) Model 3 (SE) Model 4 (SE) 
Intercept -2.6107 (0.7903) -1.02874 
(2.7837) 
-2.1267 
(3.0700) 
-3.0847 
(0.1680) 
PNNS_ALL (Continuous) -0.00929 (0.01513) - -0.02997 
(0.1276) 
- 
PNNS_ALL (Log Transformed) - -0.4599 
(0.7110) 
- - 
PNNS_ALL (Quadratic) - - 0.000210 
(0.001287) 
- 
PNNS_ALL (Grand Mean Centered) - - - -0.00947 
(0.01518) 
*-2 Log Likelihood Test* 2052.6 9 (1) 2052.6 (1) 2052.6 (2) 2052.6 (1) 
*Test Statistic (p-value)* 0.6 (>0.05) 0.6 (>0.05) 0.6 (>0.05) 0.6 (>0.05) 
***Variance**** 0.6313 (0.2195) 0.6295 
(0.2191) 
0.6285 
(0.2192) 
0.6360 (0.2222)
***AIC*** 2058.6 2058.6 2060.6 2058.6 
 
NOTE: PNNS_ALL (Grand Mean Centered) was the chosen form of the variable to be included in all following models. There 
was not much difference between Model 4 and Model 1 in either set of models, but the interpretability of penicillin-nonsusceptible 
pneumococcal isolates grand mean centered at 52% (as baseline) was better than the interpretability of 0% nonsusceptibility. 
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C4. Comparison of models 
 
 
 
Table 22a: Penicillin-nonsusceptible (all isolates) S. pneumoniae beta coefficient table (with outlier)—main effects and interaction  
 
Regressor Model 
1 
(SE) 
Model 2 
(SE) 
Model 3 
(SE) 
Model 4 
(SE) 
Model 5 
(SE)** 
Model 6 
(SE) 
Model 7 
(SE) 
Model 8 
(SE) 
Model 9 
(SE) 
Intercept -3.0251 
(0.2018
) 
-3.0235 
(0.2014) 
-2.4697 
(0.2125) 
-2.5193 
(0.2130) 
-2.6360 
(0.2202) 
-2.5882 
(0.2281) 
-2.6360 
(0.2202) 
-2.6375 
(0.2204) 
-2.6349 
(0.2201) 
PNNS_ALL (Centered-
Continuous) 
- -0.01562 
(0.01862
) 
-0.01413 
(0.01873
) 
-0.01418 
(0.01868
) 
-0.01402 
(0.01865
) 
-0.01379 
(0.01864
) 
-0.01392 
(0.01962) 
-0.01668 
(0.01879
) 
-0.01140 
(0.01938
) 
Age (Continuous) - - -0.1353 
(0.01910
) 
-0.1387 
(0.01929
) 
-0.1377 
(0.01934
) 
-0.1381 
(0.01934
) 
-0.1377 
(0.01935) 
-0.1377 
(0.01935
) 
-0.1379 
(0.01936
) 
Anydx_prior_24mo - - - 0.4575 
(0.1619) 
0.3916 
(0.1645) 
0.3977 
(0.1649) 
0.3916 
(0.1645) 
0.3912 
(0.1643) 
0.3926 
(0.1646) 
Systemic_steroid_00 - - - - 0.2673 
(0.1235) 
0.3246 
(0.1444) 
0.2673 
(0.1236) 
0.2658 
(0.1235) 
0.2651 
(0.1236) 
Acute_wheeze_1 - - - - - -0.1168 
(0.1503) 
- - - 
PNNS_ALL*AGE - - - - - - -0.00003 
(0.001899
) 
- - 
PNNS_ALL*Anydx_prior_24
mo 
- - - - - - - 0.01806 
(0.01501
) 
- 
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Table 22a (continued): Penicillin-nonsusceptible (all isolates) S. pneumoniae beta coefficient table (with outlier)—main effects and 
interaction  
 
Regressor Model 1 
(SE) 
Model 2 
(SE) 
Model 
3 
(SE) 
Model 4 
(SE) 
Model 5 
(SE)** 
Model 6 
(SE) 
Model 7 
(SE) 
Model 
8 
(SE) 
Model 9 
(SE) 
PNNS_ALL*Systemic_steroid_
00 
- - - - - - - - -0.00555 
(0.01124) 
***Variance**** 1.0673 
(0.3221) 
1.0610 
(0.3229) 
1.0738 
(0.325
4) 
1.0650 
(0.3227) 
1.0600 
(0.3214) 
1.0577 
(0.3211) 
1.0599 
(0.3213) 
1.0619 
(0.3219
) 
1.0589 
(0.3212) 
***AIC*** 2240.1 2241.1 2179.9 2174.4 2171.7 2173.1 2173.7 2172.2 2173.5 
*Italics=p-value<0.05 
**Final Model shaded in grey 
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Table 22b: Penicillin-nonsusceptible (all isolates) S. pneumoniae beta coefficient Table (without outlier)- Main Effects  
 
Regressor Model 1 
(SE) 
Model 2 
(SE) 
Model 3 (SE) Model 4 
(SE)** 
Model 5 (SE) 
Intercept -3.0867 (0.1672) -3.0847 (0.1680) -2.6287 
(0.1812) 
-2.7184 
(0.1905) 
-2.6306 
(0.2001) 
PNNS_ALL (Centered-Continuous) - -0.00947 (0.01518) -0.00763 
(0.01492) 
-0.00754 
(0.01494) 
-0.00763 
(0.01492) 
Age (Continuous) - - -0.1242 
(0.02055) 
-0.1237 
(0.02060) 
-0.1242 
(0.02058) 
Anydx_prior_24mo - - 0.4497 
(0.1697) 
0.3939 
(0.1730) 
0.4490 
(0.1718) 
Systemic_steroid_00 - - - 0.2110 
(0.1306) 
- 
Acute_wheeze_1 - - - - 0.003178 
(0.1358) 
***Variance**** 0.6289 (0.2169) 0.6360 (0.2222) 0.6062 
(0.2118) 
0.6078 
(0.2121) 
0.6063 
(0.2118) 
***AIC*** 2057.2 2058.6 2011.8 2011.2 2013.8 
*Italics=p-value<0.05 
**Final Model chosen shaded in grey 
Note: Interaction terms were tested without the outlier and similar results were seen as with the outlier therefore they were not 
included in this table for simplicity. 
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Table 23: Penicillin-resistant S. Pneumoniae beta coefficients—main effects and interaction Table  
 (Hospitals reporting resistant category n=20) 
 
Regressor Coefficient 
Symbol 
Model 
1 
(SE) 
Model 2 
(SE) 
Model 3 
(SE) 
Model 4 
(SE) 
Model 5 
(SE)** 
Model 6 
(SE) 
Model 7 
(SE) 
Model 8 
(SE) 
Intercept 
 
B0 -3.0345 
(0.2125)
-2.3790 
(0.3064) 
-1.8753 
(0.3123) 
-1.9428 
(0.3078) 
-2.1364 
(0.3157) 
-2.0914 
(0.3372) 
-2.1499 
(0.3166) 
-2.1309 
(0.3359) 
PCNRES_ALL 
(Continuous) 
B1 - -0.03424 
(0.01104) 
p-
value=0.0059
-0.03341 
(0.01077)
-0.03315 
(0.01056) 
-0.03364 
(0.01047)
-0.03794 
(0.01217) 
-0.03491 
(0.01049)
-0.03606 
(0.01238)
Age (Continuous) B2 - - -0.1243 
(0.02751)
-0.1286 
(0.02787) 
-0.1283 
(0.02810)
-0.1086 
(0.04080) 
-0.08539 
(0.02245)
-0.08537 
(0.02245)
Anydx_prior_24mo B3 - - - 0.5700 
(0.2167) 
0.4436 
(0.2215) 
0.3895 
(0.1962) 
0.2131 
(0.3478) 
0.3858 
(0.1960) 
Systemic_steroid_00 B4 - - - - 0.4661 
(0.1768) 
0.7227 
(0.1595) 
0.7182 
(0.1593) 
0.6363 
(0.2709) 
PCNRES_ALL*Age B5 - - - - - 0.001145 
(0.001659)
- - 
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Table 23 (continued): Penicillin-resistant S. Pneumoniae beta coefficients—main effects and interaction Table  
 (Hospitals reporting resistant category n=20) 
 
Regressor Coefficient 
Symbol 
Model 1
(SE) 
Model 2 
(SE) 
Model 3 
(SE) 
Model 4 
(SE) 
Model 5 
(SE)** 
Model 6 
(SE) 
Model 7 
(SE) 
Model 8 
(SE) 
PCNRES_ALL*An
ydx_prior_24mo 
B6 - - - - - - 0.00902
6 
(0.01468
) 
- 
PCNRES_ALL*Sys
temic_steroid_00 
B7 - - - - - - - 0.00417 
(0.01173) 
***Variance**** U 0.6343 
(0.2688) 
0.3197 
(0.1680) 
p-
value=0.072
3 
0.2948 
(0.1570) 
0.2735 
(0.1491) 
0.2619 
(0.1447) 
0.2892 
(0.1481) 
0.2900 
(0.1481) 
0.2907 
(0.1486) 
***Change in 
Variance from 
Model 2*** 
- N/A 0% 7.8% 14.5% 18.1% 9.5% 9.3% 9.1% 
***AIC*** - 1410.1 1168.7 1145.0 1140.7 1135.7 1365.8 1365.9 1366.1 
*Italics=p-value<0.05 
**Final Model in gray. 
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Table 24: Penicillin-nonsusceptible (blood isolates) S. Pneumoniae  beta coefficients—main effects and interaction table  
 (Hospitals reporting blood isolates n=17) 
Regressor Model 
1 
(SE) 
Model 2 
(SE) 
Model 3 
(SE) 
Model 4 
(SE) 
Model 5 
(SE) 
Model 6 
(SE) 
Model 7 
(SE) 
Model 8 
(SE) 
Model 9 
(SE)** 
Intercept 
 
-2.8467 
(0.2189) 
-2.9354 
(0.8524) 
-2.3490 
(0.8665) 
-2.4179 
(0.8655) 
-2.5921 
(0.8667) 
-2.5571 
(0.8668) 
-2.7826 
(0.9061) 
-2.5625 
(0.8733) 
-3.1577 
(0.9373) 
PCNNS_Blood 
(Continuous) 
- 0.001472 
(0.01889)
0.001799 
(0.01912) 
0.002315 
(0.01908) 
0.002557 
(0.01901) 
0.002127 
(0.01902)
0.007285 
(0.01994) 
0.001902 
(0.01916)
0.01520 
(0.02041)
Age (Continuous) - - -0.1429 
(0.02460) 
-0.1461 
(0.02482) 
-0.1434 
(0.02488) 
-0.1407 
(0.02469)
-0.07131 
(0.08079) 
-0.1436 
(0.02490)
-0.1416 
(0.02475)
Anydx_prior_24mo - - - 0.4475 
(0.2183) 
0.3556 
(0.2218) 
- - 0.1896 
(0.6726) 
- 
Systemic_steroid_00 - - - - 0.3591 
(0.1637) 
0.4036 
(0.1608) 
0.4021 
(0.1609) 
0.3603 
(0.1637) 
1.5185 
(0.5877) 
PCNNS_Blood *Age - - - - - - -0.00156 
(0.001795)
- - 
PCNNS_Blood 
*Anydx_prior_24mo 
- - - - - - - 0.003801 
(0.01447)
- 
PCNNS_Blood 
*Systemic_steroid_00 
- - - - - - - - -0.02453 
(0.01230)
***Variance**** 0.5452 
(0.2742) 
1.3216 
(0.5436) 
1.3528 
(0.5542) 
1.3460 
(0.5512) 
1.3345 
(0.5465) 
1.3370 
(0.5478) 
1.3381 
(0.5482) 
1.3338 
(0.5462) 
1.3630 
(0.5591) 
***Change in Variance 
from Model 2*** 
58.7% 0% 2.4% 1.8% 1.0% 1.2% 1.2% 0.9% 3.1% 
***AIC*** 1245.3 1282.2 1241.2 1239.3 1236.4 1236.9 1238.2 1238.4 1234.7 
*Italics=p-value<0.05 & **Final Model in gray.  
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Table 25: Penicillin-Nonsusceptible (respiratory isolates) S. Pneumoniae beta coefficients—main effects and interaction 
 (Hospitals reporting respiratory isolates n=14) 
Regressor Model 
1 
(SE) 
Model 2 
(SE) 
Model 3 
(SE) 
Model 4 
(SE) 
Model 5 
(SE) 
Model 6 
(SE)** 
Model 7 
(SE) 
Model 8 
(SE) 
Intercept 
 
-2.8484 
(0.2274)
-2.3515 
(1.0914) 
-1.7733 
(1.1124) 
-1.8046 
(1.1108) 
-2.0700 
(1.1111) 
-1.4616 
(1.1683) 
-1.9805 
(1.1150) 
-2.5812 
(1.1955) 
PCNNS_RESP (Continuous) - -0.00889 
(0.02020)
-0.00943 
(0.02050)
-0.00958 
(0.02047) 
-0.00916 
(0.02039)
-0.02071 
(0.02157) 
-0.01096 
(0.02049)
0.000519 
(0.02186)
Age (Continuous) - - -0.1299 
(0.02660)
-0.1317 
(0.02678) 
0.2295 
(0.2616) 
-0.3215 
(0.1208) 
-0.1262 
(0.02695)
-0.1267 
(0.02687)
Anydx_prior_24mo - - - 0.3643 
(0.2580) 
0.5287 
(0.1895) 
- -0.9636 
(1.1954) 
- 
Systemic_steroid_00 - - - - 0.5287 
(0.1895) 
0.5595 
(0.1873) 
0.5273 
(0.1897) 
1.5366 
(0.7431) 
PCNNS_RESP*Age - - - - - 0.003711 
(0.002181)
- - 
PCNNS_RESP*Anydx_prior_24mo - - - - - - 0.02203 
(0.02130)
- 
PCNNS_RESP*Systemic_steroid_00 - - - - - - - -0.01853 
(0.01355)
***Variance**** 0.4708 
(0.2543)
1.3211 
(0.5631) 
1.3667 
(0.5814) 
1.3601 
(0.5783) 
1.3443 
(0.5715) 
1.3743 
(0.5839) 
1.3501 
(0.5735) 
1.3520 
(0.5756) 
***Change in Variance from Model 
2*** 
64.4% 0% 3.5% 3.0% 1.8% 4.0% 2.2% 2.3% 
***AIC*** 870.3 953.6 926.3 926.4 920.6 918.4 921.5 919.4 
*Italics=p-value<0.05 &  **Final Model in gray. 
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C5. MODEL DIAGNOSTICS 
 
 
 
Figure 8: Normality of random effects 
The normal probability plot of the random effects in the main model satisfies the 
normality assumption of random effects. (PCNNS_ALL) 
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Figure 9: Normality of fixed effects 
The normal probability plot of the fixed effects in the main model satisfies the normality 
assumption of fixed effects. (PCNNS_ALL) 
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